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The T and B lymphocytes of the adaptive immune system face the challenge of correctly 
recognizing antigens originating from a vast number of rapidly evolving pathogens, while 
ignoring those pertaining to the host itself. A failure to ensure such self-tolerance may lead to 
autoimmune responses, the cause of a wide range of adverse pathologies. One self-tolerance 
mechanism is the negative selection of developing T cell progenitors with self-reactive 
capabilities in the thymus, another is the peripheral tolerance inferred by regulatory T cells 
(Tregs).  The Autoimmune Regulator (AIRE), which induces the ectopic expression of tissue-
restricted antigens in the thymus, has been indicated to be of importance in both central and 
peripheral tolerance. Mutations in the AIRE gene is the cause of autoimmune polyendocrine 
syndrome type I (APS-1), an established model disease for autoimmunity.
 
In this project, we aimed to characterize expression patterns in Tregs in APS-1, both at the protein 
and RNA levels. By assessment of the expression of pre-selected candidate genes, a number of 
subtle trends could be observed. It was indicated that the thymic output of Tregs was lower in 
APS-1 patients compared to healthy controls, but that the patient’s Tregs were capable of 
inducing expression of genes associated with an activated state. However, the observations 
failed to reach statistical significance, preventing reliable conclusions. The exception is a 
significant increase in the expression of mTOR, a downstream mediator of signaling though 
PKB/Akt. This is of interest as the inhibition of PKB/Akt by the PTEN phosphatase appear to 
be important for Treg lineage identity.  
 
When using RNA sequencing to perform a global search for gene expression perturbations, a 
number of genes were found to exhibit significant changes in expression levels in Tregs from 
APS-1 patients compared to the controls. Among the genes indicated to be significantly 
perturbed are SKI and NOTCH-1, potentially affecting TGF-b signaling. TGF-b has been 
suggested to have implications in Treg suppressive function and in the induction of the 
regulatory T cell phenotype.  
 
Further validation of these results, and elucidation of their functional implications, would be 
relevant for future work. Our hope is that continued work on Treg biology, and identification of 
clinically relevant biomarkers, can contribute to the successful implementation of this cell 
population in diagnostics and treatment of patients with immune-mediated diseases.   
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1. Introduction  
1.1 The adaptive immune system 
The vertebrate immune system is divided into two main components, termed the innate and 
adaptive immune system. The innate immune system represent a first line of defense, and 
include physical barriers and phagocytic cells recognizing pathogen-associated molecular 
patterns (PAMPs) (Janeway, 1989). The innate immune system is also capable of alerting the 
adaptive immune system, by production of attracting molecules such as chemokines (Bennouna 
et al., 2003). The responses of the adaptive immune system are slower to arise, but encompass 
an enormous capability for specificity and diversity. The ability of this system to adapt to 
encountered threats, and to retain information about such encounters, is invaluable in the arms 
race against pathogens and cancerous cells (Agrawal, Eastman and Schatz, 1998; Hedrick, 
2004).  However, the very same features of the adaptive immune system may also pose a risk 
to the host, as observed when autoimmune responses against self-tissues causes precarious 
disease states (Anderson et al., 1957; Ota et al., 1990). 
 
Among the lymphocytes of the adaptive immune system are the B cells, developing in  the bone 
marrow, and the T cells, which develop in the thymus (Cooper, Peterson and Good, 1965; 
Owen, Cooper and Raff, 1974). These populations, in turn, encompass multiple subpopulations. 
The conventional subpopulations of T cells include cytotoxic T cells (CTLs), directly involved 
in attacking virus-infected or cancerous cells (Cerottini, Nordin and Brunner, 1970; Zinkernagel 
and Doherty, 1973; Vose and Bonnard, 1982), and helper T (TH) cells, which produce a wide 
range of cytokines required by the CTLs and by B cells for activation (Tada, Okumura and 
Tokuhisa, 1978; Keene and Forman, 1982). For activation to occur, a T cell must encounter its 
specific antigen, presented on the surface of antigen-presenting cells (APCs), such as 
macrophages, dendritic cells (DCs) and B cells, bound to a major histocompatibility complex 
(MHC) molecule (Rosenthal and Shevach, 1973; Lanzavecchia, 1985; Freudenthal and 
Steinman, 1990). This interaction is dependent on the T cell receptor (TCR), but must also be 
stabilized by co-receptors. On the CTLs, the co-receptor is CD8, which interacts with MHC 
class I molecules present on the surface of APCs.  On the TH cells, the co-receptor is CD4, 
which recognize surface-bound MHC class II molecules on the APCs (Kisielow et al., 1975; 
Doyle and Strominger, 1987; Rosenstein et al., 1989).  
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Structurally, the conventional TCR consists of an  a and a b chain (Allison, Mcintyre and Bloch, 
1982), although a dg version also exist (Hayday et al., 1985; Brenner et al., 1986). The a and 
b chain each consist of a constant (C), variable (V), joining (J) and diversity (D) segment. Each 
segment is encoded by a separate genetic region, and the ability to use gene rearrangements to 
assemble different combinations of these segments allows for an astonishing diversity of TCRs 
being encoded by a relatively modest amount of genetic information. Finally, the complex also 
contains an invariant molecule termed CD3 (Garcia et al., 1996; Call et al., 2002) .  
 
1.2 Immunological education in the thymus 
In addition to its role in peripheral activation of T cells, signaling though the TCR plays a 
crucial role in T cell development in the thymus. The precursors are infiltrating hematopoietic 
stem cells from the circulation, originating from the bone marrow (Moore and Owen, 1967). 
The early lymphoid progenitors exhibit a double negative (DN) CD4-CD8- phenotype 
(Kingston, Jenkinson and Owen, 1985). As maturation proceeds, thymocytes reach the double-
positive (DP), CD4+CD8+ stage, a transition that is dependent on the successful recombination 
of the TCR b chain (Mallick et al., 1993). Depending on their interactions with MHC 
molecules, DP thymocytes may subsequently progress to the single-positive (SP) stage, by 









Figure 1.1: Development and differentiation of T cells. Bone-marrow derived, double-negative progenitors 
enter the thymus from the circulation. Following recombination of the TCR b chain, the thymocyte reaches 
the double-positive stage. The expression of either CD8 or CD4 is retained, and the single-positive thymocyte 
differentiates into one of several T cell subpopulations.  
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During the course of development, thymocytes undergo the process of immunological 
education. The enormous capacity for TCR diversity means that some immature thymocytes 
will express TCRs with no binding capacity for MCH-peptide complexes. Others may express 
TCRs with high affinity for peptides pertaining from the host itself, which could lead to a 
deleterious autoimmune response. To prevent this, the developing thymocytes are exposed to 
self-peptide-MHC complexes on APCs (Zinkernagel et al., 1978; Brocker, Riedinger and 
Karjalainen, 1997). Only thymocytes with TCR affinity above a certain threshold receive the 
required signals for continued maturation, a feature termed positive selection (Kisielow et al., 
1988; Ashton-Rickardt et al., 1994). Thymocytes exhibiting an excessively high affinity for 
self-peptide-MCH class II complexes undergo what is called negative selection, where 
induction of apoptosis ensures that development of potentially self-reactive thymocytes is 
discontinued (Ashton-Rickardt et al., 1994; Baldwin et al., 1999).  
 
For the successful deletion of potentially self-reactive T cell progenitors, the thymocytes must 
be exposed to a complete set of self-antigens for TCR engagement within the thymic 
environment. A crucial role has been attributed to thymic medullary epithelial cells (mTECs), 
present in high numbers in structures of the thymic medulla termed Hassall’s corpuscles. These 
cells exhibit promiscuous expression of genes normally restricted to specific peripheral tissues 
(Derbinski et al., 2001; Watanabe et al., 2005), a feature that has been linked to the transcription 
factor Autoimmune Regulator (AIRE) (figure 1.2) (Anderson et al., 2002). The role of AIRE 
as a transcriptional regulator has gained support by its transactivating properties and its 
interaction with the transcriptional coactivator CREB-binding protein (CBP) (Pitkänen et al., 
2000). The highest expression of AIRE has been found in mTECS (Anderson et al., 2002; 
Derbinski et al., 2005), although lower levels also has been observed other cell types such as 
dendritic cells and thymic B cells (Poliani et al., 2010; Gardner et al., 2013; Yamano et al., 
2015). Mechanistically, the AIRE-induced expression of tissue-restricted antigens (TRAs)  has 
been explained by binding to unmethylated H3K4 and subsequent induction of a chromatin 
structure in compliance with active transcription (Abramson et al., 2010). However, not all 
TRAs appear to be dependent on AIRE, and some of these AIRE-independent TRAs have  been 
indicated to be regulated by the transcription factor FezF2 (Takaba et al., 2015).  
 
At a given time, the expression of individual TRAs appear to be induced in only a small 
proportion (1-3%) of mTECs (Derbinski et al., 2008; Pinto et al., 2013; Meredith et al., 2015). 
This has puzzled researchers, as it indicates that expression of any one TRA is highly limited 
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in both time and space. While mTECs have been reported to have an autonomous APC function 
(Hinterberger et al., 2010), a possible mechanism to enhance the tempospatial expression of 
TRAs would be transfer from mTECs to hematopoietic APCs such as DCs (figure 1.2) (Koble 
and Kyewski, 2009; Hubert et al., 2011; Taniguchi et al., 2012).  
 
Roles of AIRE in mechanisms distinct from TRA expression is also increasingly being 
elucidated. For instance, it has been suggested that AIRE plays a role in the accumulation of 
dendritic cells in the thymic medulla. The elucidated molecular mechanism centers around a 
chemokine receptor, CXCR1, present on thymic DCs, and its ligand, CXL1, present on mTECs 
under regulation of AIRE (Lei et al., 2011). 
 
The process of ensuring the deletion of potential self-reactive T cell progenitors that takes place 
in the thymus is termed central tolerance (Gallegos and Bevan, 2004). However, an auxiliary 
tolerance mechanism in the periphery also exist. This leads us to the subpopulation of T cells 
termed regulatory T cells (Tregs). 
Transfer of tissue-restricted antigens










Figure 1.2: Presentation of self-antigens to a developing thymocyte. Expression of a wide range of tissue-
restricted antigens by medullary thymic epithelial cells (mTECs), induced by AIRE, ensures that the thymocyte 
encounters these self-peptides within the thymic environment. The peptides are presented directly by the mTECs, 
or transferred to other types of antigen-presenting cells such as dendritic cells.  
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1.3 Regulatory T cells 
The presence of a CD4+CD8- T lymphocyte subset with implications in the prevention of 
autoimmunity has long since been described (Sakaguchi, 1982). Should any self-reactive 
thymocytes manage to escape clonal deletion in the thymus and egress to the periphery, they 
would be prevented from raising a response towards their specific antigen by the action of these 
“suppressor cells”. For years, studies into this cell population were hampered by the lack of 
specific molecular markers, casting doubt regarding its very existence (Möller, 1988).  
However, continued efforts by the scientific community proved this to be a solvable issue, and 
today, Tregs are not only generally accepted, but considered with a high degree of interest.  
 
A molecule considered relatively early as a distinguishing hallmark of Tregs is the interleukin 2 
(IL-2) receptor alpha-chain (CD25). CD25 has been found to be present in approximately 10% 
of CD4+ T cells, although suppressive function in humans has been ascribed to a subset of 
approximately 1-2% of circulating CD4+ T cells exhibiting especially high expression  
(Sakaguchi et al., 1995; Baecher-Allan et al., 2001). The critical role played by IL-2 for 
maintaining a functional Treg population was established by the observations that injecting mice 
with anti-IL-2 antibodies resulted in reduced numbers of  CD4+CD25+ Tregs and inhibition of 
their peripheral proliferation (Setoguchi et al., 2005). A complicating factor for the use of CD25 
as a Treg marker is the notion that IL-2 also has effects as a growth factor on other T cell 
subpopulations. However, the presence of the IL-2 receptor is only transiently detected on other 
T cell subpopulations upon activation  (Robb, Munck and Smith, 1981; Taniguchi et al., 1983; 
Kuniyasu et al., 2000). 
 
Later on, Forkhead box P3 (FOXP3) was raised as a potential Treg marker protein. Encoded by 
an X-linked gene, this transcription factor appear to have vital functions in immune regulation, 
as indicated by the immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome (IPEX) that presents in males hemizygous for loss-of-function mutations in this gene 
(Bennett et al., 2001).  It has been suggested that lymphoid progenitors are dependent on 
FOXP3 as a master regulator for divergence into the Treg lineage. There is a substantial 
upregulation of FoxP3 in Tregs, and excision of FoxP3 from murine models has been observed 
to lead to severe autoimmune manifestations (Fontenot, Gavin and Rudensky, 2003).  CD4+ T 
cells transduced with FoxP3 attain regulatory function in vitro and inhibits autoimmune 
manifestations in mice deficient for FoxP3 (severe combined immunodefiency (SCID) mice). 
FOXP3 has also been found to induce the expression of several Treg-associated molecules (Hori, 
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Nomura and Sakaguchi, 2003). Intriguingly, data supports that stable expression of FoxP3 is 
retained in mature Tregs by the ability of this transcription factor to induce its own expression. 
(Gavin et al., 2007). As the expression of FoxP3 has been indicated to  not only be stable in, 
but also restricted to, Tregs (Hori, Nomura and Sakaguchi, 2003), it is considered a highly 
specific molecular marker for this T lymphocyte subpopulation. 
 
Linking FOXP3 and IL-2 is the notion that signaling through CD25 induces binding of signal 
transducer and activator of transcription 5 (STAT5) to conserved noncoding sequence 2 
(CNS2), a regulatory element in the FoxP3 promotor region (figure 1.3). Tregs from CNS2-
deficient mice have reduced FoxP3 expression and suppressive function, an increased tendency 
to lose FoxP3 expression during cell cycle progression, and a reduced ability to retain FoxP3 
expression upon challenge with pro-inflammatory cytokines or limiting IL-2. It is believed that 
in a wild type situation, a demethylated state of CNS2 facilitates STAT5 binding, thus helping 
to retain FoxP3 expression (Feng et al., 2014; Li et al., 2014).  
 
Another downstream effect of IL-2 is signaling 
though phosphatidylinositol 3-kinase (PI3K). 
Interestingly, CD4+CD25+ Tregs, but not CD4+CD25- 
T cells, appear to negatively downregulate this 
signaling pathway by recruitment of the PTEN 
phosphatase (figure 1.3) (Bensinger et al., 2004). 
This action of PTEN has been linked to Treg lineage 
stability and expression levels of CD25 (Huynh et 
al., 2015; Shrestha et al., 2015). Inhibition of PI3K 
and its downstream  mediator PKB/Akt appear to be 
crucial in the regulation of FOXP3 expression 
(Sauer et al., 2008). This is due to signaling though 
PKB/Akt having an inhibitory effect on the 
transcription factors FOXO1 and FOXO3a, required 
for the expression of FOXP3 (Merkenschlager and 
von Boehmer, 2010). In addition, an effector 
molecule downstream of PKB/Akt is mTOR, which 
is involved in modulating STAT signaling. High 
mTOR activity induce signaling through STAT4 
Figure 1.3: Effects of IL-2 signaling on Tregs. IL-2 
leads to STAT5-binding to the CNS2 promoter element. 
In addition, IL-2 signaling leads to recruitment of 
PTEN phosphatase and inhibition of the PKB/Akt 
pathway, so that inhibition of the transcription factors 
FOXO1 and FOXO3a is avoided. Both of these 








and STAT6, involved in divergence into TH lineages. The activity of STAT5, by contrast, 
appear to be upregulated upon mTOR inhibition (figure 1.3)  (Delgoffe et al., 2009; Shan et al., 
2015).  
 
1.4 Natural and induced regulatory T cells 
Although some Tregs may obtain cellular identity during development in the thymus, the 
existence of an additional subset, which diverge into the Treg lineage after emigration to the 
periphery, has also been indicated. These two subsets have been termed natural (n) and induced 
(i) Tregs, respectively (Chen et al., 2003; Fantini et al., 2004; Knoechel et al., 2005; Jia et al., 
2018). It has also been concluded that, albeit the expression of some canonical Treg genes are 
enhanced in iTregs, among them FOXP3, this do apply to several other genes considered to be 
part of the Treg signature transcriptome  (Hill et al., 2007).  It has been indicated that signaling 
through the PI3K-Akt-mTOR pathway (Sauer et al., 2008) and TGF-b plays major roles in this 
peripheral induction of Treg lineage identity (Chen et al., 2003; Fantini et al., 2004; Jia et al., 
2018). 
 
Several potential markers for differentiation between iTregs and nTregs have been suggested. One 
candidate, HELIOS, is encoded by the Ikaros zinc finger transcription factor family member 2 
gene (IKZF2). It has been suggested that HELIOS is restricted to the thymic-derived subset of  
regulatory T cells (Thornton et al., 2010), In addition, it has been indicated that HELIOS 
expression correlates with suppressive capacity (Zabransky et al., 2012). HELIOS has been 
found to bind to promoter regions of target genes essential for Treg survival, and to induce 
signaling trough the CD25-STAT5 pathway (Kim et al., 2015).  Another gene, Neuropilin-1, 
has also been suggested to be expressed exclusively by nTregs (Yadav et al., 2012). It has been 
proposed that Neuropilin-1 functions as a receptor for Semaphorin 4a, which upon activation 
recruits PTEN phosphatase to the immunologic synapse (Delgoffe et al., 2013). 
 
1.5 Development of regulatory T cells  
Similar to other T cell populations, Treg progenitors are assessed for their affinity for self-
peptides during thymic maturation. As for other T cell subsets, the transfer of tissue-restricted 
antigens from AIRE-expressing mTECs to hematopoietic APCs appears to play an important 
role in TCR avidity assessment, although some Treg generation has been attributed to the 
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autonomous antigen-presenting activity of mTECs (Aschenbrenner et al., 2007; Perry et al., 
2014; Mouri et al., 2017). 
 
It has been proposed, due to correlation between FoxP3 expression and TCR signaling, that 
FoxP3 expression is induced in thymocytes by interaction of their TCRs with peptide-MHC 
class II complexes with an intermediate avidity (fgure 1.4). Lower avidity would lead to 
positive selection and maturation into other T cell lineages,  while higher avidity would lead to 
negative selection and clonal deletion (Fontenot, Gavin and Rudensky, 2003). It appears that 
the development of Tregs may be divided into two steps, where the first is dependent on TCR 
signaling.  In the second, antigen-independent stage, cells are able to express FOXP3 after 
exposure to IL-2, with no requirement for APCs (Lio and Hsieh, 2008). 
Figure 1.4: The TCR avidity model of T cell development. During thymic maturation, the thymocytes are 
exposed to self-peptides bound to MHC class II molecules on antigen-presenting cells. For thymocytes exhibiting 
TCRs with excessively low or excessively high avidity for such self-peptide-MHC class II complexes, maturation 
is discontinued. Thymocytes exhibiting TCRs with moderate avidity survive and develop into mature T cells, such 
as CD8+ cytotoxic T cells or CD4+ helper T cells. Thymocytes with avidity for self-peptide-MHC class II 
sufficiently low for survival, but higher than the avidity leading to commitment to other T cell lineages, mature 
into regulatory T cells. Figure modified from Gregersen and Behrens, 2006. 
 
The TCR avidity model has been supported by the observation of diminished negative selection 
and increased Treg emergence upon reduction of Mhc-II expression on a population of cells with 
APC activity in the murine thymus (Hinterberger et al., 2010). Further, murine studies 
employing a panel of TCRs with a broad range of sensitivity for a specific antigen, found that 
the extent of Treg generation correlates with efficiency of antigen recognition (Lee et al., 2012). 
On the other hand, complicating the avidity model is the finding that both CD4+FOXPP3+ Tregs 
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and CD4+FOXP3- non-Tregs could be selected for by identical TCRs, although this discovery  
has been debated  (Wojciech et al., 2014; Lin et al., 2016).  
 
An implication of the TCR avidity model is that it infers a strict requirement for Treg lineage 
stability, as Tregs exhibit a certain level of affinity for self-peptide-MHC class II complexes. 
This means that loss of Treg cellular identity could result in “ex-Tregs” with self-reactive 
capabilities (Zhou et al., 2009; Bhela et al., 2017). 
 
1.6 Peripheral maintenance of regulatory T cells  
In addition to its role during Treg development, TCR engagement has been ascribed an important 
role in the maintenance  of Treg lineage identity and in the activation of Tregs after emigration to 
the periphery (Vahl et al., 2014; Bluestone et al., 2015; Liu et al., 2015; Leventhal et al., 2016). 
An intriguing suggestion is the existence of a peripheral “memory Treg” pool, where Tregs 
resulting from earlier encounters with antigens remain in a resting state for an extended period 
of time. This is supported by studies using mouse models, where induction treatment with a 
specific antigen resulted in a persistent FOXP3+ cell population, capable of activation and 
suppressive function upon re-exposure to antigen (Rosenblum et al., 2011).  
 
The presence of a peripheral pool of Tregs could be especially important upon aging. It has long 
since been known that a gradual involution of the thymus occurs after puberty (Simpson, Gray 
and Beck, 1975). Consistent with this, generation of T cells and TCR diversity appear to be 
reduced with increased age. This raises the question of whether Treg generation is affected upon 
aging, and whether other mechanisms may be involved in maintaining a functional Treg 
repertoire in adult individuals. Puzzlingly, it appears that the frequency of nTregs is increased, 
not reduced, upon aging (Gregg et al., 2005; Booth et al., 2010; Hou et al., 2017). An intriguing 
suggestion is that enhanced Treg generation could be acting as a compensatory mechanism to 
alleviate the issue of reduced central tolerance induction (Oh et al., 2017).  
 
A complicating factor is the finding that mature Tregs may recirculate into the adult thymus 
(Thiault et al., 2015; Cowan et al., 2018). However, the functional relevance of this remains 
unknown. One suggestion is that recirculating Tregs negatively affect de novo Treg generation 
due to increased competition for IL-2 (Thiault et al., 2015). Interestingly, this recirculation of 
Tregs also appears to be influenced by AIRE (Cowan et al., 2018).  
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1.7 Regulatory T cell function 
The mature Tregs in the periphery are poised to react upon encounters with self-reactive 
lymphocytes. Several molecules have been described to be involved in the suppressive function 
of Tregs, among them IL-2, TGF-b,  CTLA-4, GITR, CD39 and CD73 (figure 1.5).  
 
IL-2 
It has been suggested that due to the high expression of CD25, Tregs reduce the availability of 
the CD25 ligand, IL-2, of other T cells. CD4+FOXP3+ cells have also been reported to inhibit 
IL-2 production, and their suppression of CD4+FOXP3- T cells could be overcome by addition 
of IL-2 (Fontenot et al., 2005). Also, the main source of IL-2 for Tregs appear to be other T cells. 
This would constitute a negative feedback loop, where T cells activated during an immune 
response sustain the proliferation of Tregs by producing IL-2, and thus aid in their own 
suppression (Setoguchi et al., 2005). A dire illustration of the importance of this negative 
feedback loop is provided by familial hemaphagocytic lymphohistiocytosis, where its 
dysregulation may yield fatal results (Humblet-Baron et al., 2016).    
 
TGF-b 
In vitro studies have suggested that Treg suppressive function is cell contact dependent, due to 
the observation that it is abolished if Tregs are separated from target cells by a semi-permeable 
membrane (Thornton and Shevach, 1998; Hori, Nomura and Sakaguchi, 2003). Whereas this 
does not negate the possibility of a contribution of contact-independent mechanisms, such as 
the IL-2 “sink” model, it infers a requirement for additional, contact-dependent mechanisms. 
One suggestion involves cell surface-bound TGF-b1 on Tregs (Nakamura, Kitani and Strober, 
2001). However, others have found that Tregs can mediate suppressor function in the absence of 
TGF-b1 (Piccirillo et al., 2002). 
 
CTLA-4 
Another molecule suggested to play a role in the suppressive function of Tregs is T lymphocyte-
associated protein-4 (CTLA-4 or CD152). While CTLA-4 normally is expressed exclusively 
upon activation in T cells (Salomon et al., 2000), it is constitutively expressed in Tregs under the 
control of FOXP3 (Hori, Nomura and Sakaguchi, 2003). Mice with specific CTLA-4-
deficiency in Tregs tend to develop severe autoimmune manifestations (Wing et al., 2008). 
Imaging studies have reported that both naïve CD4+CD25- T cells and CD4+CD25+ Tregs 
	 16	
aggregate around DCs, but that Tregs do so more readily. Following this initial, antigen-
dependent aggregation, an antigen-independent down-regulation of B7-1 (CD80) and B7-2 
(CD86) receptors were observed on DCs.  This second step appears to be mediated by CTLA-
4, and the final result is a failure of DCs to activate naïve T cells with reactivity towards specific 
antigens (Onishi et al., 2008). In accordance with this, CTLA-4-lacking Tregs are reported to be 
incapable of preventing upregulation of B7-1 and B7-2 on DCs upon activation in culture (Wing 
et al., 2008). In addition, CLTA-4 induces increased clustering, and thus increased avidity, of 
lymphocyte function-associated antigen-1 (LFA-1), an integrin associated with the previously 
discussed aggregation step  (Schneider et al., 2005).  
 
CTLA-4 signaling through B7-1 and B7-2 receptors on DCs also leads to induction of the 
enzyme 2,3-dioxygenase (IDO), which catalyzes tryptophan metabolism. This can aid in T cell 
down-regulation by depleting the T cells of tryptophan and by yielding immunotoxic 
byproducts such as kynurenines (Mellor et al., 2002; Orabona et al., 2004; Fallarino et al., 
2006). Alternatively, binding of CTLA-4 to B7 receptors on activated T cells could directly 
mediate their suppression though pathway distinct from that activated in DCs. This suggestion 
is based on the observations that B7-deficient TH cells were resistant to Treg-mediated 
suppression in vitro, and that transfer of B7-deficient CD4+ T cells into mice induced 
autoimmune disease which could not be inhibited by also transferring Tregs (Paust et al., 2004).  
 
GITR/TNFRSF18 
Another protein involved in Treg function is the glucocorticoid-induced tumor necrosis factor 
receptor family-related protein (Gitr), prevalent in CD4+ CD25+ T cells and in CD4+CD8-
CD25+ thymocytes in naïve, wild-type mice. The observations that GITR stimulation abolishes 
Treg mediated suppression indicates a role of GITR in abrogation of this self-tolerance 
mechanism. It has been suggested that GITR stimulation may antagonize the suppressive 
signals delivered through TCRs and CTLA-4 (Shimizu et al., 2002). 
 
CD39 and CD73 
Finally, roles in suppressive function have been ascribed to ectonucleoside triphosphate 
diphosphohydrolase 1 (ENTPD-1/CD39) and 5’ nucleotidase ecto (NT5E/CD73), ectoenzymes 
present on the surface of Tregs. CD39 functions in the hydrolysis of di- and triphosphates to their 
respective nucleosides, such as AMP. CD73, in turn, hydrolyzes AMP to adenosine and 
inorganic phosphate. The resulting alteration in adenosine levels in the environment 
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surrounding the Treg is believed to mediate suppressive signaling though inhibitory A2A 




















1.8 Autoimmune polyendocrine syndrome type I as a model disease for autoimmunity 
Loss-of-function mutations AIRE has been established as the cause of autoimmune 
polyendocrine syndrome type 1 (APS-1) (Nagamine et al., 1997; Aaltonen et al., 1997), also 
referred to as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) 
(Perheentupa, 2006). The clinical hallmarks of APS-1 are chronic mucocutaneous candidiasis, 
hypoparathyroidism and adrenal insufficiency, although a number of other manifestations also 
occur frequently (figure 1.6). Diagnosis is set by the presence of at least two of this triad, but 
patients may exhibit pathologies long before this criterion is fulfilled. APS-1 is a rare condition, 
with an estimated prevalence in the Norwegian population of 1:90 000 (Wolff et al., 2007; 
Husebye et al., 2009).  
Figure 1.5: Proposed mechanisms of Treg suppressive function. By high expression of CD25, the receptor for 
IL-2, Tregs are suggested to function as “IL-2 sinks”, reducing the availability of other T cells for IL-2. By 
expression of CD39 and CD73 on the cell surface, Tregs are suggested increase the concentration of adenosine, 
which has inhibitory effects by binding to A2A receptors on T cells. Signals from TGF-b on the cell surface of 
Tregs is suggested to negatively affect the activation of naïve T cells. CTLA-4 on the Treg surface mediates 
downmodulation of B7-1/B7-2 receptors on dendritic cells, leaving fewer available receptors for binding of the 
alternative ligand, CD28, present on T cells. Binding of CTLA-4 to B7-1/B7-2 receptor also induces 2,3-
dioxygenase (IDO) to metabolize tryptophan, yielding immunotoxic kyrunenines as byproducts.  
	 18	
1.9 Tolerance impairment in APS-1 
It has been proposed that the AIRE 
deficiency in APS-1 patients leads to a 
reduction in expression of TRAs in mature 
mTECs, thus hampering the tolerogenic 
role played by these cells. In addition, 
AIRE deficiency has been linked to issues 
with mTEC development (Yano et al., 
2008). A resulting failure in TRA 
presentation by mTECs during education 
of T cell progenitors could be expected to 
lead to self-reactive T cells escaping 
thymic clonal deletion. These T cells may 
then attack self-tissues, ultimately 
resulting in overt autoimmune disease. 
Indeed, a failure in negative selection in 
APS-1 has been reported by several studies  
(Anderson et al., 2002, 2005, Liston et 
al., 2003, 2004).  
 
In addition, a deficiency in Tregs could be 
argued to be a contributing cause of the autoimmune manifestations observed in APS-1 patients. 
A link between AIRE and the thymic development of certain specificities of Tregs has been 
indicated (Malchow et al., 2013), and it appears that Aire expression in the newborn thymus is 
a prerequisite for correct Treg development  in mice (Guerau-de-Arellano et al., 2009; Yang et 
al., 2015). An interesting possibility that has been raised is that of an AIRE-mediated 
divergence of autoreactive T cells into the Treg lineage. A comparative study of T cells from 
Aire-/-and Aire+/+ mice indicated that TCR specificities found to be overrepresented among 
CD4+FOXP3- T cells from the Aire-deficient mice, were found among the CD4+FOXP3+ Tregs 
in their Aire-sufficient counterparts (Malchow et al., 2016).  
 
One study reported that CD4+CD25hi cells from APS-1 patients were unable to prevent a 
proliferative response of CD25- T cells upon general stimulation. When assessing for an 
antigen-specific response, by contrast, AIRE-deficient and –sufficient CD4+CD25hi cells were 
Figure 1.6: Clinical manifestations of APS-1. The clinical 
picture is varied, with a large number of potential 
manifestations. Of special note is the classical triad of chronic 
mucocutaneous candidiosis, hypoparathyroidism and adrenal 
insufficiency. Figure from Husebye et al., 2009.  
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equal in suppressive capability. In addition, the TCR repertoire in patient CD4+CD25hi cells 
appeared to be skewed toward the TCR repertoire of naïve T cells (Kekäläinen et al., 2007). 
These findings could be interpreted as an indication of a generalized effect of AIRE-
insufficiency, not only restricted to specific antigens. This could perhaps be attributed to effects 
of AIRE during Treg development.  
 
Quantitative effects on the Treg population has also been reported in APS-1 (Ryan et al., 2005; 
Wolff et al., 2010). Flow cytometry studies of PBMC (peripheral blood mononuclear cells) 
from 19 APS-1 patients and age-and sex-matched healthy controls found that the frequency of 
CD4+CD25+FoxP3+ Tregs was significantly reduced in the APS-1 patients (Wolff et al., 2010).  
 
1.10 Development and peripheral maintenance of regulatory T cells in APS-1 
A Treg deficiency in APS-1 could be due to issues both in the thymic development and the 
peripheral maintenance of Tregs.  A study in favor of the former found no significant peripheral 
conversion into Tregs from other CD4+ cells in healthy subjects, suggesting the thymus as the 
major source of Treg impairment. In addition, the CDR3 length appeared to be increased in the 
Tregs of APS-1 patients compared to healthy subjects (Koivula et al., 2017). This is interesting 
due to the notion that CDR3 length appears to be gradually shortened during the development 
of T cell progenitors in the thymus (Matsutani et al., 2007, 2011; Niemi et al., 2015). Thus, the 
increased length observed in the Tregs in APS-1 patients may be argued to be a result of issues 
with this central lymphoid developmental process.  
 
Others favor the view that peripheral Treg maintenance may be impaired in APS-1 and that this 
is a crucial cause of Treg insufficiency. For instance, it was observed that a reduction in FOXP3 
expression in Tregs from APS-1 patients was less apparent in recent thymic emigrants. The 
possibility of a slowly dividing reservoir of naïve, peripheral Treg cells in healthy individuals 
was raised, and that a failure in the maintenance of this reservoir afflict the ability of APS-1 
patients to mount Treg responses against self-reactive cells (Laakso et al., 2010). This model 
corresponds well with the previously mentioned report of a Treg “memory” pool (Rosenblum et 
al., 2011).  
 
In further support of peripheral effects, Aire-expressing cells in secondary lymphoid tissues and 
the spleen appear to induce the expression on a set of TRAs distinct from those expressed in 
mTECs (Gardner et al., 2008). While expression levels are significantly lower compared to 
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mTECs, there is evidence for Aire also being present in peripheral DCs. These DCs have been 
indicated to express genes correlated with a tolerogenic phenotype, such as IDO (Poliani et al., 
2010).  It is suggested that expression of Aire infers an immature status on DCs and reduces 
their prowess in T cell activation. Aire-deficiency in DCs has been found to inhibit the 
differentiation of naïve CD4+ cells into the Treg lineage, while promoting differentiation into 
other lineages such as TH17 cells  (Huo et al., 2018).  
 
1.11 Hypothesis and aims 
Our hypothesis is that the AIRE deficiency in APS-1 patients have an impact on the 
development or differentiation of Tregs. To explore this, we aim to characterize gene expression 
patterns in Tregs from APS-1 patients, both at the RNA and protein level. The resulting 
knowledge could help us validate previous reports regarding impairment of Tregs-mediated 
tolerance in APS-1 patients, and enhance our understanding of the underlying mechanisms. 
This, in turn, could prove valuable for the overall goal of identifying molecular targets for 
implementation of Tregs in diagnostics and therapy, potentially with transfer value to other 
autoimmune diseases.  
 
Aims: 
1.) Method development 
a. Develop methodology for obtaining pure suspensions of Tregs 
b. Set up a flow cytometry panel for relevant target proteins 
c. Optimize a real-time qPCR protocol for use for assessment of RNA 
expression, both at bulk sample and single cell-level 
d. Optimize a low input protocol for whole RNA-sequencing 
 
2.) Assessment of gene expression patterns in APS-1 
a. Assessment of the expression of selected candidate genes at the protein level 
by use of flow cytometry of PBMC samples from APS-1 patients and controls 
b. Assessment of the expression of selected candidate genes at the RNA level by 
use of real-time qPCR, conventional PCR and RNA sequencing, using Treg 
samples from APS-1 patients and controls 
c. Perform a global search for gene expression perturbations in Tregs from APS-1 





Reagents and chemicals 
Supplier Ref. No. 
Ficoll-Paque Miltenyi Biotec 17-1440-03 
Dulbecco’s Phosphate Buffered Saline Sigma Life Science D8537 
AB serum Sigma Life Science H4522 
Dimethyl Sulphoxide (DMSO) Hybri-Max Sigma Life Science D2650 
MACSxpress Treg Isolation Kit, human Miltenyi Biotec 130-109-557 
Rinsing buffer:                   Automacs Rinsing Solution 99.5% 





Flow cytometry buffer:        Phosphate buffered saline 99.5% 
   MACS BSA Stock solution 0.5% 




Tryphan Blue stain Invitrogen  T10282 
BD Pharm Lyse BD Biosciences 555899 
Anti-CD4 FITC, clone M-T466 Miltenyi Biotec 130-080-501 
Anti-CD25 PE, clone 4E3 Miltenyi Biotec 130-091-024 
Anti-CD127 APC, clone MB15-18C9 Miltenyi Biotec 130-098-121 
130-113-969 
Anti FoxP3-APC, clone 3G3 Miltenyi Biotec 130-098-121 
Anti-human FoxP3 Staining Set eBioscience 77-5774-40 
BD CompBead Plus Anti-mouse Ig BD  51-9006274 
BD CompBeads Negative control BD 51-9006227 
UtraPure BSA, 50 mg/ml Abion AM2616 
Absolutt Alkohol Kemetyl Norge 200-578-6 
b-mercaptoethanol Aldrich chemistry M6250 
RNeasy Mini Kit Quiagen 74106 
Rneasy Plus Micro Kit Quiagen 74034 
Rnase Free DNAse set Quiagen 79254 
High capacity RNA-to-cDNA kit Applied Bisosystems 4387406 
SuperScript III first-stand cDNA synthesis kit Invitrogen 18080-051 
TaqMan Gene Expression Master Mix Applied Biosystems  4369016 

















DEPC Treated Water Ambion AM9906 
Nuclease Free Water VWR chemicals 436912C 
Betaine solution, 5M Sigma Aldrich B0300 
AmpliTaq Gold DNA Polymerase with Gold Buffer and 
MgCl2 
Applied Biosystems 4311814 
Custom PCR primers  
(Details in supplementary information table S.3)                   
Eurogentec  
B2M   
IKZF4   
PECAM-1   
CXCR3   
CD3d   
mTOR   
TOLLIP   
CCR4   
 Invitrogen A15629/A15630- 
FOXO1  Hs00131544 
CCR5  Hs00715153 
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Neuropilin-1  Hs00318297 
TBE buffer AccuGene BE50843 
Agarose NA GE Healthcare 17-0554-02 
PAGE GelRed Nucleic Acid Gel Stain Biotium 41008 
Amplisize molecular ruler, 50-2000 bp BioRad 1708200 
Gel Loading Dye blue BioLabs B70215 
Illustra ExoStar  Life Sciences US77720V 
BigDye Terminator v1.1 Sequencing Kit Applied Biosystems 4336774 
RNA 6000 Pico Reagents Agilent Technologies  5067-1513 
High Sensitivity DNA reagents Agilent Technologies 5067-4626 
Smart-Seq v4 Ultra Low Input RNA Kit Takara  634895 
AMPure XP  Beckman Coulter A63880 
Nextera XT DNA Library Preparation Kit Illumina 15032350 
Nextera XT Index Kit 
Live/dead Fixable Yellow Dead Cell stain kit 
Illumina 15055293 
Life technologies L34959 
Fc block BD 564219 
Anti-CD4 AF700, clone RPA-T4 BD 557922 
Anti-CD8 PerCP-Cy5.5, clone SKI BD 565310 
Anti-CD25 PE-Cy7 clone 2A3 BD 335789 
Anti-CD3 V500, clone UCHT1 BD 561416 
Anti-CD45RA APC-H7, clone HI100 BD 560674 
Anti-CD31 BV786, clone L133.1 BD 744757 
Anti-CTLA4 BV421, clone BN13 Biolegend 369606 
Anti-FOXP3 PE-CF594, clone 259D/C7 BD 563955 
Anti-Nrp1 BV650, clone HIL-7R-M21 BD 743131 
Anti-Ki67, clone 20Raj1 Invitrogen 11-5699-42 
Anti-CD39 PE, clone ebioA1 Invitrogen 12-0399-42 
Anti-Helios APC, clone 22F6 Biolegend 137222 
OneComp eBeads Invitrogen 01-1111-41 
   
 
Equipment and consumables   
ART Barrier reload insert pipette tips:                          
  1000 µl 
200 µl   
100 µl 
10 µl 




Clip-Tip reload pipette tips 20 µl Thermo Fischer 94420218 
Finnpipette F1 pipettes Thermo Fischer   
Fastpette Labnet  
Pipette tips, 10 ml Sterilin 475110 
Disposable pipettes VWR 1612-1613 
Centrifuge tubes:                                                            50 ml 
   15 ml 







Round-bottom tubes, 5 ml Corning Science 352063 
Cryogenic vials 1.5 ml Nalgene 5000-1020 
BD Vacutainer, heparin 10 ml BD 367526  




SB2 rotator Stuart  
Countess cell counting chamber slides Invitrogen C10283 
MacsExspress separator Miltenyi Biotec 130-042-302 
MidiMACS separator  Miltenyi Biotec 130-042-302 
LS Columns Miltenyi Biotec 130-042-401  
MicroAmp Optical 96 well reaction plate Applied Biosystems N8010560 
MicroAmp Optical Adhesive film Applied Biosystems 201501347 
5810R Centrifuge Eppendorf  




Countess Automated cell counter Thermo Fischer 
Accuri C6 flow cytometer BD 
LSR Fortessa flow cytometer BD  
FACS Aria SORP BD 
NanoDrop ND-1000 Spectrophotometer Saveen Werner 
ABI Prism 7900HT sequence detection system Thermo Fisher 
GelDoc EZ gel documentation system BioRad 
ABI 3730 Sequencer Applied Biosystems 
Agilent 2100 Bioanalyzer Agilent technologies 
HiSeq4000 sequencing system Illumina 
 
Software  
FlowJo 10.4 FlowJo, LLC 
ND-1000 3.8 Thermo Fisher 
SDS 2.3 Applied Biosystems 
GelDoc EZ ImageLab 3 BioRad 
CLC main workbench 8.0 Quiagen 
2100 Expert Agilent Technologies 












Kinetic energy 26 joules minicentrifuge VWR C1413V 
Thermomixer Eppendorf  
QuiaShredder Columns Quiagen 79656  
MicroAmp 8-tupe strip, 0.2 µl Applied Biosystems N8010580 
MicroAmp 8-cap strip Applied Biosystems N8010535 
GeneAmp 9700 PCR system Applied Biosystems  
384 Well Multiply PCR Plate Sarstedt 72.1984.202 
Gel tray, comb, casting chamber General supplier  
Hoefer HE33 electrophoresis unit Pharmacia Biotech 80-6052-45 
Electrophoresis power supply Amercham Biosciences  
Chip Priming station Agilent Technologies 5065-4401 
RNA Pico Chips Agilent Technologies 5067-1530  
DNA High Sensitivity Chips Agilent technologies  5067-4626  
IKA vortex mixer Agilent technologies  
SMARTer-Seq Magnetic Separator Takara 635011 
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3. Methods 
3.1 Experimental pipeline and choice of methods 
The experimental pipeline is illustrated in figure 3.1. Blood samples were collected from 
APS-1 patients and controls, and isolated cells were distributed across the applied techniques.   
 
One of the main techniques used in this project is flow cytometry, where cells are stained using 
flurochrome-conjugated antibodies specific for molecular targets of interest. The fluorescence 
resulting from antibody binding is then measured by the flow cytometer. The flurochromes are 
excited by lasers, and the emitted light is collected through filters allowing the passage of 
particular wavelengths. An additional feature is the ability to observe how light is scattered by 
the cells. Larger cells will result in a higher forward scatter compared to smaller cells, and more 
complex (granular) cells will result in higher side scatter compared to less complex cells. The 
same features are exploited when using fluorescence activated cell sorting (FACS).  
 
To assess the expression level of selected genes at the RNA level, real-time quantitative qPCR 
is used. The selected approach is the TaqMan technology, as this is considered a highly sensitive 
method (Löseke et al., 2003). The method is based on annealing of probe sequences containing 
a 3’ fluorochome and a 5’ quencher to the template. As the TaqMan polymerase has 5’ 
exonuclease activity, amplification will release the fluorochrome from the quencher. This 
results in a fluorescent signal of a magnitude corresponding to the number of times a template 
has been amplified. This means that the more template sequences are present in the initial 
sample, the larger the signal will be. Output is given in the form of a CT value, which reflects 
the number of amplification cycles that is required for the signal to reach a threshold value. To 
facilitate comparison across samples, the CT values are normalized based on the results for a 
 Figure 3.1: Overview of the experimental pipeline CD4+CD25+CD127-. Treg, were isolated from peripheral 
blood by magnetic bead separation and FACS. Peripheral blood mononuclear cells (PBMC) were isolated from 
peripheral blood by density gradient centrifugation. RNA from both Tregs and PBMC were used for qPCR and 
conventional PCR. In addition, RNA-seq was performed for smaller Treg samples. For assessment of the expression 
of  Treg-associated genes at the protein level, flow cytometry studies of PBMC were performed.  
Blood sample in EDTA tube (15-25 ml) Blood sample in heparin tube (5-10 ml)
Bead-separation and FACS sorting of CD4+CD25+CD127- cells Isolation of PBMC
2 million PBMC 1 million PBMC5000 or 10 000 cells 18 000 - 400 000 cells
RNA-seq (n=4 patients, 4 controls) qPCR (n=4 patients, 8 controls) Flow Cyt. (n=6 patients, 7 controls)
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reference gene, expected to be present at the same relative amount in all samples (Livak and 
Schmittgen, 2001). 
 
The development of high-throughput sequencing methodologies has facilitated transcriptome 
analysis by RNA sequencing. First, RNA isolated from cell samples is reverse-transcribed into 
complementary DNA. By using poly-T sequences as primers for the reverse transcription, the 
resulting cDNA will pertain from mRNA sequences. If the RNA input for cDNA synthesis is 
low, it may be necessary to perform a pre-amplification of the cDNA, primed by random 
hexamer sequences. After cDNA synthesis, a library of cDNA fragments of suitable size for 
the selected sequencing platform must be created. To make the run on the sequencing platform 
more cost-effective, it may be desired to pool the libraries resulting from different samples and 
run them together on a single lane. This can be done by introducing unique, short index-
sequences in each library (Kukurba and Motgomery, 2015). 
 
3.2 Ethical aspects 
The project was conducted in compliance with the Declaration of Helsinki, and approved by 
the Regional Ethical Committee of Western Norway (approval number 2009/2555 and 
2018/1417). All patients had given written informed consent. Controls samples were obtained 
from the Haukeland University Hospital blood bank, and all blood donors had given written 
consent to samples being used in research.  
 
3.3 Patients and controls 
The APS-1 patients (4 Females, 2 males, range 40-64 years old, mean age 51 years old) all had 
mutations in the AIRE gene, and 5 fulfilled the criteria for clinical diagnosis (supplementary 
information table S.1). All patients were included in the protein profiling study, patients 1-4 
were included in the RNA study. The control samples (1 female, 11 males, range 25-66 years 
old, mean age 43 years old) were obtained from healthy blood donors (supplementary 
information table S.2). 
 
3.4 PBMC isolation by density gradient centrifugation 
Fresh blood samples (5-10 ml) were collected in heparin tubes and diluted 1:1 in PBS. The 
samples were added on top of Ficoll-Paque (2:1) prior to centrifugation for 30 min at 500 xg at 
20°C. The peripheral blood mononuclear cell (PBMC) layer was collected and washed by 
addition of 10 ml PBS and centrifugation for 15 min at 350xg at 4°C. Cell counting was 
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performed by use of a Countess automatic cell counter. Approximately 2x106 cells, to be used 
for real-time quantitative PCR, were lysed in 600 µl RNeasy Lysis (RLT) buffer, and stored at 
-80°C. Batches of 1x106 cells, to be used for flow cytometry, were resuspended in 500 µl AB 
serum 10% (v/v) DMSO and stored at -80°C for 24-72 hours, then at -150°C until use.  
 
3.5 Treg isolation by magnetic bead separation 
Fresh blood samples (15-25 ml) were collected in EDTA tubes. Tregs were isolated using 
MacsExpress Treg isolation kit according to the manufacturer’s protocol. Briefly, peripheral 
blood, MacsExpress Treg isolation buffer and Macsexpress Treg isolation cocktail was mixed 
(20:10:1) prior to incubation in an overhead rotator for 10 min. The sample was then placed in 
a MacsExpress separator for 15 min, the supernatant was centrifuged for 10 min at 350xg 20°C, 
and the pellet was resuspended in 4 ml rinsing buffer (Automacs Rinsing solution with 0.5% 
BSA). This suspension was then passed through an LS column placed in a MidiMacs separator. 
After washing with 4 ml rinsing buffer, the column was removed from the MidiMacs separator 
and the cells were eluted by adding 2 ml rinsing buffer and using a plunger. The eluate was 
centrifuged for 10 min at 350xg 4°C and cells were resuspended in 300 µl rinsing buffer. 
 
3.6 Fluorescence activated cell sorting (FACS) 
Cells from the magnetic bead separation were stained with the antibodies a-CD4-FITC 
(dilution factor 1:20), a-CD25-PE (dilution factor 1:10) and a-CD127-APC (dilution factor 
1:10 for Cat. No 130-098-121, 1:50 for Cat. No. 130-113-969). The dilution factors had been 
chosen based on initial experiments using two different dilution factors. After 30 min 
incubation in the dark at 4°C, the cells were washed by addition of 2 ml rinsing buffer and 
centrifugation for 10 min at 350xg at 4°C. The pellet was then resuspended in 500 µl rinsing 
buffer.  The CD4+CD25+CD127lo cells were sorted into 300 µl PBS by use of a FACS Aria 
SORP (figure 3.2). Excitation was performed by 488 nm and 635 nm lasers, emitted light was 
collected though a 525/50 filter for FITC, a 575/25 filter for PE, and a 660/20 filter for APC. 
The yield varied from 18 000 to 400 000 cells.  The cells were centrifuged for 10 min at 350xg 
4°C and the pellet was lysed in 350 µl RLT plus buffer. The lysate was either immediately 
subjected to the RNA isolation protocol or stored at -80°C.  In addition, samples of 5000 and 
10 000 CD4+CD25hiCD127lo cells, meant for RNA sequencing, were sorted into 75 µl RLT 
plus buffer 10% v/v b-mercaptoethanol, and the lysate was stored at -80°C. For each sample, 
an unstained control was also prepared from 100 µl peripheral blood from the same individual. 
	 27	
Erythrocytes were lysed by addition of 2 ml 1X BD pharm lyse buffer and incubation for 10 
min at room temperature. The cells were pelleted by centrifugation as before, and washed with 
2 ml rinsing buffer. The pellet was resuspended in 350 µl rinsing buffer and run on the FACS 

















3.7 Validation of the Treg isolation protocol using flow cytometry 
The reasoning behind using the surface marker CD127 is that this marker has been reported to 
have a negative correlation with FOXP3 (Liu et al., 2006). It should thus be possible to use this 
marker as a FOXP3 surrogate, avoiding the need for cell permeabilization. To determine 
whether this inverse correlation could be observed, and to validate the success of the magnetic 
bead separation protocol, flow cytometry of PBMC and bead separated cells was used. The 
frozen PBMC were thawed at 37°C, 200 µl AB serum was added, and the cells were washed 
by addition of 10 ml PBS and centrifugation at 350xg at 4°C for 10 min. The pellet was 
resuspended in 100 µl flow cytometry buffer (PBS with 0.5% BSA), and the surface markers 
(CD4, CD25 and CD127) were stained as previously. For FOXP3 staining, fixation and 
Figure 3.2: Gating strategy used during FACS sorting of CD4+CD25+CD127lo cells. First, a gate was 
set for live cells, using a FSC area vs. SSC area plot, and cells having passed singly though the lasers were 
identified on a FSC area vs. FSC height plot. Then, FITC fluorescence vs. SSC-A was used to gate for the 




































permeabilization was performed by use of the anti-human FoxP3 staining set according to the 
manufacturer’s protocol. Briefly, cells were spun down as before and resuspended in 1 ml 
fix/perm buffer. After incubation at 4°C for 45 min, 2 ml 1X permeabilization buffer was added, 
and the cells were centrifuged at 500xg 20°C for 5 min. The pellet was resuspended in 100 µl 
permeabilization buffer, and a-FOXP3-APC was added (dilution factor 1:10). After incubation 
for 30 min in the dark at 4°C, the cells were washed twice by adding 2 ml diluted 
permeabilization buffer and centrifugation as before. The pellet was then resuspended in 350 
µl flow cytometry buffer. In addition to the stained cell samples, an unstained sample was 
included for each separate experiment. Compensation controls were prepared using BD 
compensation beads. For each antibody, 1 drop compensation beads and 1 drop negative control 
beads were stained as the cell samples. All samples were run on an Accuri c6 flow cytometer 
until 100 000 (PBMC) or 60 000 (bead separated cells) events had been collected. Excitation 
was performed by 488 nm and 640 nm lasers, and emitted light was collected though a 530/30 
band pass filter for FITC, a 585/40 band pass filter for PE, and a 675/25 band pass filter for 
APC. The data analysis was performed using FlowJo software version 10.1.  
 
One sample of bulk sorted cells was used for validation of the sorting procedure. After FACS 
sorting, the cells were stained with FOXP3-APC as described previously, the sample was run 
on the flow cytometer until 75 000 events had been collected. 
 
3.8 Treg protein profiling by flow cytometry 
The Treg flow cytometry panel (table 3.1) was inspired by a workshop regarding Tregs in clinical 
samples (Santegoets et al., 2015). PBMC from the 6 patients and 7 controls (supplementary 
information tables S.1 and S.2) were thawed as before, and between 5x105 and 1x106 cells were 
resuspended in 100 µl flow cytometry buffer. The surface markers were stained using the 
chosen antibody concentrations, by the same protocol as previously explained. Staining of 
intracellular markers (FOXP3, Helios, and Ki-67) was subsequently performed using the 
eBioscience Anti-human FOXP3 Staining Set as previously explained, with some changes. The 
incubation in fixation/permeabilization buffer was increased from 45 min to overnight to ensure 
complete fixation of all cells. After the first wash step in permeabilization buffer, 2 µl Fc block 
was added to cells resuspended in the 100 µl permabilization buffer, in order to prevent non-
specific antibody binding to Fc receptor on immune cells. The cells were then incubated for 15 
min at 4°C in the dark prior to staining. Samples were run on a LSR Fortessa flow cytometer 
until 100 000-300 000 events had been collected in the lymphocyte gate. Excitation was 
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performed by use of 407 nm, 488 nm, 561 nm and 640 nm lasers, and emitted light was collected 
though the filters listed in table 3.1.  
 
The dilution factors for all antibodies were chosen based on initial titration experiments 
applying five different antibody concentrations (representative experiments in figure 3.3). For 
abundant markers, PBMC from healthy controls were split into samples of 200 000 cells and 
stained using the relevant antibody. For the rare markers, PBMC were mixed 1:5 with bead-
separated cells from the same healthy control, and cells were stained using the a-CD4-Alexa 










For all antibodies except a-CD4, a-CD8 and a-CD3, fluorescence minus one (FMO) controls 
were performed. Compensation controls were prepared by staining of OneComp eBeads, for 
the Live/dead fixable yellow stain, single-stained PBMC were used as compensation control. 
The compensation controls were performed in order to account for “spillage” of emitted light, 
meaning that light from one fluochrome is detected by the channel designated for another 
fluorochrome.  
Figure 3.3: Titration of the a-CD3-V500 (top) and a-FOXP3-PE-CF594 (bottom) antibodies. First, a plot of 
forward scatter area versus forward scatter height was used to gate for cells having passed singly by the lasers. 
Then, a plot of forward scatter area versus side scatter area was used to gate for lymphocytes. For the FOXP3 
titration, an additional gate was set for CD4+ cells based on a forward scatter area versus Alexa fluor 700 
fluorescence plot. Then, for both antibodies, a concatenated plot showing the fluorescence pertaining from the 
respective antibody for five different samples, stained by the use of different dilution factors, was created. These 
concatenated plots formed the basis of the decisions regarding which dilution factors to use when staining the 
patient and control samples, based on the best possible separation of the negative and positive cell populations. 
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3.9 RNA isolation 
For cell numbers <5x105, RNA was isolated by using the RNeasy Micro Plus kit, while for 
samples of >5x105 cells, the RNeasy Mini kit was used. In both cases, the manufacturer’s 
protocol was followed. The lysate was passed through a QuiaShredder column, and for the 
RNeasy Micro Plus Kit, genomic DNA was removed by passage through a gDNA eliminator 
column. One volume of 70% ethanol was added, and the samples were passed through an 
RNeasy MiniElute (for the micro kit) or Mini (for the mini kit) spin column. After washing 
with 350 µl buffer RW1, on-column DNase digestion was performed by using the RNase-Free 
DNase set. DNase I was diluted 1:8 in RDD buffer, and 80 µl was added to the column 
membrane prior to incubation for 15 min at room temperature.  The column was washed with 
350 µl buffer RW1, 500 µl buffer RPE and either 500 µl 80% ethanol (micro kit) or 500 µl RPE 
(mini kit). RNA was eluted in 14 µl (micro kit) or 30 µl (mini kit) RNAse free H2O, which was 








Target Fluorochrome Dilution factor Excitation Filter for emittance 
CD3 V500 1:20 407 nm 670/30 band pass 
CD4 Alexa Fluor 700 1:160 640 nm 730/45 band pass 
CD8 PerCP-Cy5.5 1:20 488 nm 695/40 band pass 
CD25/IL-2RA PE-Cy7 1:40 561 nm 780/60 band pass 
CD45RA APC-H7 1:80 640 nm 780/60 band pass 
CD152/CTLA-4 BV421 1:20 407 nm 450/50 band pass 
CD39/ENTPD-1 PE 1:500 561 nm 582/15 band pass 
CD31/PECAM-1 BV785 1:160 407 nm 780/60 band pass 
CD304/Neuropilin-1 BV650 1:80 407 nm 670/30 band pass 
FOXP3 PE-CF594 1:10 561 nm 610/20 band pass 
Helios/IKZF2 APC 1:40 640 nm 670/14 band pass 
Ki-67 FITC 1:10 488 nm  530/30 band pass 
Dead cell stain Q-dot585 1:1000 407 nm 585/42 band pass 
Table 3.1: Overview of the flow cytometry panel, with targets, fluorochomes, dilution factors and 
the wavelengths used for excitation and collection of emission.   
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Figure 3.4: An example of Agilent Bioanalyzer output for a high quality RNA sample. The sample is from 
control 1 Tregs and was used for RNA-seq.  On the gel image, two clearly distinct bands, pertaining to 18S and 
28S rRNA, are observed, and no smearing pertaining from degraded RNA fragments is present.  On the 
fluorescence versus nucleotide number plot, the 18S and 28S rRNA are seen as two distinct peaks, and the 
baseline is otherwise stable. The RNA Integrity Number (RIN) of 9,2 also reflects high RNA quality.  
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The RNA quality was assessed by the Agilent Bioanalyzer, using the Agilent 6000 Pico kit 
according to manufacturer’s protocol (figure 3.4). The RNA concentration was determined by 
use of a NanoDrop ND-1000 Spectrophotometer, and the samples were stored at -80°C if not 
immediately used. 
 
3.10 Real-time quantitative PCR of Treg candidate genes in bulk samples 
First-strand cDNA synthesis was performed using the high capacity RNA-to-cDNA kit, 45 ng 
RNA was mixed with 10X RT buffer (50% v/v) and RT enzyme (5% v/v) to a total volume of 
20 µl and placed in a thermal cycler at 37°C for 60 min, then 95°C for 5 min. qPCR was 
performed using TaqMan gene expression assays. For each gene expression assay, cDNA (25% 
v/v), probe/primer mix (5% v/v) (supplementary information table S.4), TaqMan Gene 
Expression Master mix (48% v/v) and DEPC H2O was mixed to a total volume of 30 µl. The 
reaction mixture was transferred in triplicates to a clear 384 well plate. A negative control was 
prepared for each gene expression assay on every separate run. The plate was placed in a ABI 
prism sequence detection system and run at the following program: 50°C 2 min, 95°C 10 min, 
then 45 cycles of 95°C 15s, 60°C 1 min.  
 
3.11 Real-time quantitative PCR of single-cell samples 
96-well plates were prepared with 5 µl buffer (Ultrapure BSA (2 mg/µl), DEPC H2O) in each 
well. Single CD4+CD25+CD127- cells were sorted into separate wells using a FACS Aria 
SORP. cDNA synthesis was performed by use of the SuperScript III First-Stand synthesis kit. 
The sample in each well was mixed with random hexamers (5% v/v), oligo(dT)20 primer (5% 
v/v), dNTPs (0.5 mM) and DEPC H2O (8% v/v) to a total volume of 6.5 µl. The plate was 
incubated at 65°C 5 min, and cDNA synthesis was set up by the addition of 10x RT buffer (5% 
v/v), MgCl2 (1.25 mM), DTT (5 mM), RNase OUT (5% v/v), SuperScript III RT (2.5%) and 
DEPC-treated H2O to a total volume of 10 µl. The plate was then run at the following program 
in a thermal cycler: 25°C 5 min, 50°C 60 min, 55°C 15 min, 70°C 15 min, 4°C storage. The 
plate was stored at -20°C until use. After thawing on ice, each sample was diluted 1:2 with 
DEPC-treated H2O, and then used for real-time qPCR. The protocols were as for the bulk qPCR 
samples, with two exceptions: Triplicates were not achievable due to limited material, so only 
one reaction was run per well, and the cycle number was increased to 50. 
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3.12 Conventional PCR 
A conventional PCR protocol was developed as a semi-quantitative approach in order to assess 
the expression of a larger number of candidate genes. The following reaction mix was set up to 
a final volume of 25 µl: PCR gold buffer 10x (10% v/v), MgCl2 (1.5 µM), dNTP (0.8 µM), 
betaine (1.4 M), forward primer (0.4 µM), reverse primer (0.4 µM), enzyme (0.8% v/v), 
nuclease-free H2O (35.2% v/v), cDNA (prepared as explained for bulk qPCR, 4% v/v). The 
reaction was run at the following thermal cycler program: 96°C 10 min, then 35 cycles of 95°C 
20 s, 55°C 20 s, 72°C 1 min, followed by 72°C 7 min and 4°C storage. The PCR protocol was 
performed for PBMC and Tregs from control 1 (results not shown). Unfortunately, running the 
PCR on patient Treg samples for comparison with control Treg samples was not possible due to 
the limited amount of sample material available.   
 
During initial testing, PCR products were sequenced to ensure that that they corresponded to 
the correct gene. First, 5 µl PCR product was rinsed by addition of 2 µl ExoStar and subjection 
to thermal cycler program 37°C 15 min, 80°C 15 min. For sequencing, the BigDye Terminator 
V.1.1 kit was used, reaction mixture with total volume 10 µl contained rinsed PCR product 
(35% v/v), BigDye v 1.1 (10% v/v), BigDye buffer (20% v/v), either fw or rv primer (0.2 mM), 
nuclease-free H2O (25% v/v). The reaction was then run on the following thermal cycler 
program: 96°C 5 min, then 30 cycles of 96°C 15 s, 50°C 15 s, 60°C 2 min, 4°C storage. The 
samples were sequenced by the Medical Genetics Department at Haukeland University Hospital 
by use of a ABI 3730 sequencer, and data analysis was performed using CLC main workbench 
8.0 software. 
 
3.13 RNA sequencing 
RNA-seq was performed using the SMART-Seq v4 Ultra Low Input RNA Kit according to the 
manufacturer’s protocol. For 10 000 cell samples, the RNA was diluted 1:2, while RNA from 
5000 cell samples was kept undiluted. Then, 1 µl 10x reaction buffer (10 X lysis buffer with 
RNase Inhibitor, 5% v/v) and 2 µl 3’ SMART-Seq CDC Primer IIA (12 µM) was added to 9.5 
µl sample, and tubes were incubated at 72°C for 3 min, then on ice for 2 min. First-Strand 
cDNA synthesis reaction mix was set up as follows to a total volume of 20 µl: 5x Ultra-Low 
First-Strand Buffer (20% v/v), SMART-Seq v4 oligonucleotide (5% v/v), RNase Inhibitor 
(2.5% v/v), SMARTScribe Reverse Transcriptase (10% v/v), and the prepared sample from the 
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previous step. The tubes were then run on the thermal cycler program 42°C 90 min, 70°C 10 
min, 4°C storage.  
 
Reaction mix for cDNA amplification was then set up to a total volume of 50 µl: 2x SeqAmp 
PCR Buffer (50% v/v), PCR Primer 11A (0.24 µM), SeqAmp DNA Polymerase (2% v/v), 
Nuclease-free H2O (6% v/v), and the cDNA from the previous step. The tubes were subjected 
to the following thermal cycler program: 95°C 1 min, then 10 cycles of 98°C 10 s, 65°C 30 s, 
68°C 3 min, then 72°C 10 min, 4 °C storage.  The decision to use 10 cycles was based on the 
two initial experiments, where 7 and 10 PCR cycles was tested.  
 
The amplified cDNA was purified by use of the Agencourt AMPure XP Kit. First, 1 µl 10 X 
lysis buffer from the SMART-Seq v4 Kit was added to each sample, prior to addition of 50 µl 
Agencourt AMPure XP beads and 8 min incubation at room temperature. Samples were then 
placed in a magnetic stand for 5 min. The supernatant was removed, and the beads were washed 
twice with 200 µl 80% ethanol while still in the magnet. The samples were spun briefly and 
placed back in the magnet for an additional 30s for removal of residual ethanol. After aspiration 
of ethanol, the pellet was allowed to dry for 5-10 min., and 17 µl elution buffer from the Smart-
Seq v4 kit was added. The samples were removed from the magnet and allowed to rehydrate 
for 2 min. Then, samples were placed back in the magnet and incubated for at least 1 min, 
before supernatants containing cDNA were transferred to new tubes. The purified cDNA was 
assessed by an Agilent Bioanalyzer by use of the Agilent High Sensitivity DNA Kit (figure 3.5) 
according to the manufacturer’s protocol. The samples were stored at -20°C.  
 
Library preparation was performed using the Nextera XT DNA Library Preparation kit and the 
Nextera XT Index kit according to the manufacturer’s protocol. The cDNA was diluted 
according to the results from the Agilent Bioanalyzer (1:10 for samples with peak at around 
100 FU, 1:5 for samples with peak at around 50 FU), and 5 µl diluted sample was mixed with 
10 µl Tagment DNA buffer. Next, 5 µl Amplicon Tagment Mix was added, and the samples 
were centrifuged at 280xg 20°C 1 min. The samples were then placed in a thermal cycler at 
55°C for 5 min, with a subsequent temperature drop. As soon as the temperature reached 10°C, 
5 µl neutralize tagment buffer was added to each well. Samples were centrifuged as before and 
incubated at room temperature for 5 min. Unique combinations of i5 (5 µl) and i7 (5 µl) index 
adapters were added to each respective sample. Then, 15 µl Nextera PCR Master Mix was 
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added, and the samples were centrifuged as before. The samples were subjected to the following 
thermal cycler program: 72°C 3 min, 95°C 30s, then 12 cycles of 95°C 10s, 55°C 30s, 72°C 
30s, then 72°C 5 min and 10°C storage. The samples were purified using AMPPure XP beads 
as before, with the exception of shaking at 1800 rpm for 2 min. prior to the 8 min. incubation 
period, and elution in 52.5 µl resuspension buffer from the Nextera XT kit. The samples were 
then assessed by the Agilent high sensitivity DNA kit utilizing the Agilent Bioanalyzer (figure 
3.5) according to manufacturer’s protocol. Sequencing of the products was performed by the 
Bergen Genomics core facility, using a HiSeq4000 sequencer according to the Illumina TruSeq 
Stranded mRNA protocol. Sequencing depth was approximately 100 million reads per sample. 
The data analysis was performed in collaboration with PhD candidate Amund Holte Berger, 
Department of Clincal Sciences, Unversity of Bergen. Quality control was performed using the 
FastQC software, and reads were aligned to the GRCh38.p12 reference transcriptome by the 




3.14 Statistical analysis 
For the qPCR and flow cytometry data, a non-parametric, two-tailed Mann-Whitney test was 
performed by using Graphpad software. This test considers differences in medians, shape and 
spread between two groups (Hart, 2001). The use of a non-parametric test was chosen due to 
the low number of samples, preventing an assumption of a normal distribution. Results were 
found statistical significant if P < 0.05. For the RNA-seq data analysis, P-values were obtained 
by application of the WALD test. Calculation of FDR (false discovery rate) values was 
subsequently performed  by use of the Bejamini-Hockberg transformation (Benjamini and 
Hochberg, 1995).  This was done to account for the notion that an increase number of tests 
increases the likelihood of false positives. Results were found statistical significant if FDR < 
0.05. 
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Figure 3.5: An example of Agilent Bioanalyzer output for the amplified cDNA (left) and after library 
preparation (right) from control 1. The results for the amplified cDNA indicate the presence of cDNA fragments, 
with lengths above 1000 bp.  The results after library preparation indicate the presence of cDNA fragments of a 
concentration and size range suitable for sequencing.   
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4. Results 
4.1 Validation of the Treg isolation protocol 
Flow cytometry was used to assess the success of the magnetic bead separation, and to 
determine whether there was an inverse correlation between the expression of CD127 and 
FOXP3. PBMC and bead-separated cells from one donor were stained for CD4, CD25 and 






Figure 4.1: Results from flow cytometry assessment of PBMC (A and B) and bead separated cells (C 
and D) stained with CD4, CD25 and either CD127 or FOXP3. First, a plot of forward scatter area versus 
side scatter area is used to gate for lymphocytes, and a plot of forward scatter area versus forward scatter 
height is used to gate for cells having passed by the lasers as single cells. Then, a plot of forward scatter area 
versus FITC fluorescence is used to gate for CD4+ cells. Finally, a plot of APC fluorescence versus PE 
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The frequency of Tregs, defined either as CD4+CD25+CD127lo or CD4+CD25+FOXP3+, was 
found to be markedly increased after the magnetic bead separation. However, there still 
remained a number of non-Tregs. The observed frequency was similar regardless of whether 















To assess whether the sorted CD4+CD25+CD127lo cells were also FOXP3+, FOXP3 staining 
and flow cytometric assessment was performed on one sample of sorted cells from a 
representative healthy control. When an unstained PBMC sample was used to define the 
negative population, approximately 94% of the sorted cells were FOXP3+, after removing cells 
that had not passed singly by the lasers and debris (figure 4.2).  
 
4.2 Protein profiling study using flow cytometry 
The antibody panel (table 3.1) was used for assessment of PBMC samples from 6 APS-1 
patients and 7 controls (representative data in figures 4.3 and 4.4). A comparison of the 
frequency of positive cells for the respective markers for the patients and the controls was 
performed using Graphpad software (figure 4.5, table 4.1). 
Figure 4.2: FOXP3-staining of CD4+CD25+CD127lo cells after FACS. For the sorted cell sample, a cell gate 
was set on a forward scatter area versus side scatter area plot, and a single cell gate was set on a forward 
scatter versus side scatter height plot. Then, an APC fluorescence versus cell count plot was used to gate for 
FOXP+ and FOXP3- cells. The negative population was defined based on an unstained PBMC sample. The 
gating strategy for the PBMC was the same, except for the cell gate being replaced by a lymphocyte gate on the 
forward scatter area versus side scatter area plot.  
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Figure 4.3: The result from assessment of patient 1 PBMC by the flow cytometry antibody panel. First, 
a plot of forward scatter area versus side scatter area was used to gate for lymphocytes, followed by a forward 
scatter area versus forward scatter height plot in order to gate for cells having passed singly by the lasers. 
Then, a plot of forward scatter area versus QDot 585 fluorescence was used to gate for live cells. A plot of 
forward scatter area versus V500 fluorescence was used to gate for T cells, defined as CD3+. To gate for 
single-positive CD4+CD8- cells, a plot of PerCy-Cy5.5 fluorescence versus Alexa fluor 700 fluorescence was 
used. Then, a gate was set for the Tregs, defined as CD25+FOXP3+, on a plot of PE-CF594 fluorescence versus 
Pe-Cy7 fluorescence. For this population, plots of forward scatter area versus the fluorescence of the relevant 
fluorochrome was used to define cells positive for Neuropilin-1, Ki-67, CD31/Pecam-1+, CD39/ENTPD-1+, 
CD152/CTLA-4+ and Helios+, respectively.  
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Figure 4.4: The result from assessment of control 1 PBMC by the flow cytometry antibody panel. First, 
a plot of forward scatter area versus side scatter area was used to gate for lymphocytes, followed by a forward 
scatter area versus forward scatter height plot in order to gate for cells having passed singly by the lasers. 
Then, a plot of forward scatter area versus QDot 585 fluorescence was used to gate for live cells. A plot of 
forward scatter area versus V500 fluorescence was used to gate for T cells, defined as CD3+. To gate for 
single-positive CD4+CD8- cells, a plot of PerCy-Cy5.5 fluorescence versus Alexa fluor 700 fluorescence was 
used. Then, a gate was set for the Tregs, defined as CD25+FOXP3+, on a plot of PE-CF594 fluorescence versus 
Pe-Cy7 fluorescence. For this population, plots of forward scatter area versus the fluorescence of the relevant 
fluorochrome was used to define cells positive for Neuropilin-1, Ki-67, CD31/Pecam-1+, CD39/ENTPD-1+, 
CD152/CTLA-4+ and Helios+, respectively.  
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Figure 4.5: A comparison of the frequency of positive cells for the respective markers, within the 
respective parent gates, in PBMC from APS-1 patients and controls. The plots are based on the gating 
levels as shown in figures 4.3 and 4.4. The horizontal lines indicate medians, and the error bars indicate 












































































































































































































































































Based on the median percentage frequency values, the frequency of CD3+ cells and CD4+CD8-  
cells were similar between APS-1 patients and controls. The frequency of CD25+FOXP3+ cells 
was also relatively similar between the two groups, although these cells have a slightly reduced 
frequency in the APS-1 patients compared to the controls. Within the CD25+FOXP+ population, 
the frequency of cells positive for CD31, a marker of recent thymic emigrants (Kimmig et al., 
2002), CD45RA, a marker of naïve cells (Michie et al., 1992), and Helios was found to be 
slightly higher in the control group compared to the patient group. For Ki-67, a marker of 
cellular proliferation (Gerdes et al., 1983), Neuropilin-1, CD39, and CTLA-4, the opposite 
result was found, with the highest frequency of positive cells being found in the patient group. 
However, for all the tested markers, the differences between APS-1 patients and controls were 
small, and the spread between individuals relatively large. Based on a two-tailed Mann-
Whitney test, none of the observed differences was found to be significant.  
 
When performing the flow cytometry staining protocol, the CTLA-4 staining was performed 
prior to permeabilization, so that the resulting fluorescence would pertain to cell surface-bound 
CTLA-4 only. To assess the effect of also staining for intracellular CTLA-4, a sample of control 
1 PBMC was stained both before and after permeabilization. The result of surface staining alone 
was compared with the results from the main protocol. When combining intracellular and cell 
surface staining for CTLA-4, a large increase was observed in the frequency of CTLA-4+ cells 
within the CD3+CD4+CD8-CD25+ population (29.1%) compared to the frequency obtained with 
cell surface staining alone (2.67%) (figure 4.6). 
 Median frequency within parent 
gate (%), patients 
Median frequency within parent 
gate (%), controls 
P-value 
CD3+ 71.20 73.70 0.7922 
CD4+CD8- 56.70 53.25 >0.9999 
CD25+FOXP3- 3.745 4.970 0.1375 
Nrp-1+ 0.6350 0.3300 0.0670 
Ki67+ 8.120 4.000 0.1807 
CD31+ 6.035 13.70 0.2949 
CD39+ 44.90 37.50 0.5338 
CTLA-4+ 6.330 2.310 0.0670 
Helios+ 72.35 80.80 0.2343 
CD45RA+ 6.735 11.10 0.6282 
Table 4.1: Median frequency of cells positive for the respective markers, within the parent gates as indicated 











Figure 4.6: The result of performing both cell surface and intracellular staining for CD152/CTLA-4 (A), 
versus performing cell surface staining only (B). Gates were set for lymphocytes, singe cells, live cells, CD3+ 
cells and CD4+CD8- cells as before. Then, a forward scatter area versus PE-Cy7 fluorescence were used to gate 
for cells showing high expression of CD25. Finally, a plot of forward scatter area versus BV412 fluorescence was 
used to gate for CTLA-4+ cells within the CD25+ population. When performing both cell surface and intracellular 
staining, 29.1% of CD25+ cells were also CTLA-4+, while the corresponding number when performing cell surface 
staining only was 2,57%. 
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Previous reports (Booth et al., 2010) have indicated that the frequency of CD45RA+ Tregs 
decreases with age. To assess whether such an effect was present, a plot was created showing 
the age of all controls versus the observed CD45RA+ frequency within the CD3+CD4+CD8-
CD25+FOXP3+ population (figure 4.7). With the exception of one control exhibiting a high 










4.3 Assessment of gene expression at the RNA level 
4.3.A Real-time quantitative PCR of candidate genes 
PBMC and Treg bulk samples from 4 APS-1 patients and 8 healthy controls were assessed for 
expression levels of FOXP3, AIRE and HELIOS by the qPCR protocol. The PBMC samples 
were also assessed for expression levels of CTLA-4, ENTPD-1 and GITR, the Treg samples 
were not assessed for these last three due to limited material availability. 
 
 For each individual, fold change values for the expression of the assessed genes in Treg relative 
to PBMC were calculated (figure 4.8). For FOXP3, there was a large increase in expression 
levels in Tregs compared to the PBMC, with median fold change values above 130 both for the 
patients and controls. CTLA-4 and HELIOS were also indicated to have a substantial increase 
in expression levels in the Tregs compared to the PBMC, with a median fold change value of 36 
for CTLA-4, and of 22 and 14 for HELIOS, for the patient and controls, respectively. For the 
remaining genes, increases in expressing levels in the Tregs compared to the PBMC were also 
observed, in descending order GITR, AIRE and ENTPD-1. However, these increases were 
relatively small. 
 
Figure 4.7: A plot of control age versus CD45RA+ frequency in the CD3+CD4+CD8-CD25+FOXP3+ 
population. The general trend is a decreasing frequency with increasing age. 





































Pairwise comparisons of the median  DCT values of the patients and the controls were performed 
for each respective gene (figure 4.9). For FOXP3, AIRE, and HELIOS, this was done both for 
PBMC and Treg samples. For CTLA-4, ENTPD-1, and GITR, this was done for PBMC samples 
only. No clear differences were observed in the DCT values between the patient and the control 
group, for any of the genes, regardless of whether PBMC or Treg samples were assessed.  
Figure 4.8: Fold change of the expression of each of the assessed genes in Tregs compared to PBMC from 
the same individual. The bars indicate median fold change values within the patient or control group, and the 
error bars indicate interquartile ranges. Fold change values were calculated by the formula 2"∆∆$% , where 
DDCT represent the difference between normalized CT values for Tregs and PBMC from the same individual. A 
large fold change was observed for FOXP3, resulting in the need to place this gene in a separate plot (left) in 
order to ensure suitable scaling of the Y-axis. For the remaining genes (right), increases were also observed, 
with the largest fold change values observed for CTLA-4 and HELIOS. Smaller fold change values for GITR, 
AIRE and CD39 indicated that slight increases in expression levels in Tregs compared to PBMC was present 



































































































































Figure 4.9: Comparative plots of median DCT values for the patients and controls, both for 
PBMC and Treg samples, for each of the genes assessed by qPCR. Based on the pairwise 
comparisons of median DCT values, no large differences appear to exist in the expression levels of 
FOXP3, AIRE, HELIOS, CTLA-4, CD39, or GITR between the patients and controls. This holds true 






































































































The qPCR protocol was also tested on single cell samples (data not shown), using the gene 
expression assays for B2M and FOXP3. The resulting raw CT values were relatively high for 
B2M, reflecting the very low initial amount of template, and lacking altogether for FOXP3. 
When assessing a 10 cell-sample, the situation was slightly improved, but still far from the 
values that would allow reliable assessment. Attempts at optimization of the current qPCR 
protocol were done, but found insufficient to alleviate the issue.  
 
4.3.B Conventional PCR of candidate genes 
A protocol for the assessment of the expression of a number of other candidate genes based on 
conventional PCR was developed. Based on the obtained results for one representative control 
(figure 4.10), none of these genes were indicated to have increased levels of expression in Treg 
compared to PBMC. Thus, they were not considered to be highly Treg-specific. As they could 
still have important functions in Tregs, comparative experiments using Treg samples from APS-
1 patients and controls were planned. Unfortunately, the lack of sufficient sample material from 
the APS-1 patients prevented the execution of such experiments.  
 
 
Fgure 4.10: The result of conventional PCR for selected candidate genes using PBMC (A) and Treg (B) 
samples from control 1, visualized by agarose gel electrophoresis. None of the assessed genes appeared 
to be highly increased in expression in the Treg sample compared to the PBMC sample.  
A B
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4.3.C RNA sequencing 
RNA-sequencing was performed on samples of 5000 CD4+CD25+CD127- Tregs from 4 patients 
and 4 healthy controls, and standard quality controls were executed. Thereafter, an assessment 
of candidate genes of particular interest (supplementary information table S.4), was performed. 
For each of these genes, pairwise comparisons of the TPM (transcript per million) values for 
the APS-1 patients and controls were performed (figure 4.12). As for the qPCR results, most 
did not exhibit significant changes, however, a significant increase in mTOR expression was 
observed for the APS-1 patients (figure 4.11). The significance level was set based on FDR 







Figure 4.11: Log2 fold change values for the candidate genes in Tregs from APS-1 patients relative to 
controls, as determined by the RNA-seq experiment.  Based on the calculated FDR values, the only gene 
exhibiting a significant change in expression level in the Tregs from the patient group was mTOR.  
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Figure 4.12: Pairwise comparison of the expression levels of selected candidate genes as determined by 
RNA-seq, indicated by TMP (transcript per million) values, between APS-1 patients and controls. The 
assessed genes were FOXP3, CTLA-4, IKZF2 (encoding HELIOS), Neuropilin-1, PECAM-1, ENTPD-1 
(encoding CD39), TNFRSF18 (encoding GITR), MKI-67, PTPRC (encoding CD45), IKZF4, CXCR3, CD3d, 
mTOR, TOLLIP, FOXO1, CCR5, CCR4 and NT5E (Encoding CD73). The horizontal lines indicate median 




Next, a global search for expression level perturbations was performed. A volcano plot was 
created (figure 4.13), showing the log2 fold change values versus -log10 FDR values. On the 
volcano plot, the genes found to have the most extensive changes in expression levels in the 
APS-1 patients compared to the controls were identified. A plot of log2 fold change versus gene 
count was also created. This plot indicated that, although the majority of the genes exhibited no 
substantial changes in gene expression levels in the APS-1 patients (indicated by log2 fold 
change values close to zero), a number exhibited such changes. The presence of genes with 
increased expression levels for the APS-1 patients compared to controls (indicated by positive 
log2 fold change values) was especially evident. For the genes exhibiting the highest decrease 
(figure 4.14) and increase (figure 4.15) in the APS-1 patients compared to the controls, pairwise 
comparisons were done based on median TPM values.   
Figure 4.13: Vulcano plot of genes (top) showing log2 fold change for APS-1 patients relative to controls, 
versus –log10  FDR, and a plot of the log2 fold change versus gene count (bottom).  Genes exhibiting 
significant changes in expression levels between patients and controls, defined as having FDR values of 0.05 
or lower, are indicated in red in the volcano plot.  
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Figure 4.14: Pairwise comparison of the genes found to exhibit the largest decrease in expression levels 
in the APS-1 patients compared to controls, based on the RNA-se experiment. The horizontal lines 
indicate medians among each group, measured as trancripts per million (TPM). All differences were found 
significant based on the calculated FDR values. 
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Figure 4.15: Pairwise comparison of the expression levels of the genes found to exhibit the largest 
increase in expression levels in the APS-1 patients compared to controls, based on the RNA-seq 
experiment. The horizontal lines indicate medians among each group, measured as transcripts per million 
(TPM). All differences were found significant based on the calculated FDR values.  
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Due to methodological challenges with the SMART-Seq V.4 kit, the cDNA synthesis and pre-
amplification was performed in two separate runs. This could potentially cause batch effects, 
where the variation in the obtained data is largely explained by variations between the two runs. 
To assess whether such a batch effect was present in the obtained data set, a PCA plot was 
created (figure 4.16). On this plot, the x-axis corresponds to the factor explaining the largest 
amount of variation (PC1), and the y-axis corresponds to the factor explain the second largest 
amount of variation (PC2). If a major cause of the observed variation was a batch effect, the 
samples from the two different runs would be seen as two distinct clusters on the PCA plot. 
Such an effect is not observed. In the same manner, the PCA plot was used to determine whether 
the AIRE condition, age or sex was a major cause of the observed variation in the data set 
(figure 4.16). As the data points do not cluster according to any of these parameters, this do not 
appear to be the case.  
 
Figure 4.16: PCA plots based on the RNA-seq experiment, where data points are identified according to 
batch (A), AIRE condition (B), age (C) or sex (D). The axes represent the factors explaining the largest and 
second largest amount of the observed variance, termed PC1 and PC2, respectively. The assessed samples do not 
cluster according to any of the assessed paramteres, indicating that these are not major causes of the observed 








5.1 Tregs can be isolated from peripheral blood samples by bead separation followed by 
fluorescence-activated cell sorting 
We have here developed a protocol for the separation of Tregs from peripheral blood, and shown 
that this protocol yields Treg samples of high purity. To validate the separation protocol, both 
PBMC and cells separated by the use of magnetic beads were stained by antibodies targeting 
CD4, CD25 and either CD127 or FOXP3. Based on assessment by flow cytometry (figure 4.1), 
it was indicated that, after separation using magnetic beads, the frequency of Tregs was markedly 
increased compared to PBMC. This held true whether the Tregs were defined as 
CD4+CD25+CD127lo or CD4+CD25+FOXP3+.  Although these results indicate that a relatively 
high frequency of Tregs could be obtained by the bead separation protocol, the purity was still 
considered insufficient for downstream applications, calling for the need for complementing 
isolation procedures. Further, the correlation between CD127lo and FOXP3+ frequency 
underlines the reported possibility of using CD127 as a surrogate marker for FOXP3 (Liu et al., 
2006). 
 
The findings resulted in the development of a protocol for Treg isolation by FACS, based on 
surface marker staining only (figure 3.2). By this approach, the need for fixation and 
permeabilization was avoided, a treatment which could restrict the utility of the sorted cells in 
downstream applications. To assess whether sorted CD4+CD25+CD127lo cells also expressed 
FOXP3, the sorted cells were stained with an antibody targeting FOXP3. By flow cytometric 
assessment, it was indicated that the frequency of FOXP3+ cells among the sorted 
CD4+CD25+CD127- population was 94.4% in a representative experiment, after removal of 
debris and cells not having passed singly by the lasers (figure 4.2). This was taken as an 
indication that the Treg purity after FACS was sufficiently high to proceed with downstream 
protocols.  
 
5.2 The expression of selected candidate genes is overall similar in APS-1 patients and 
controls 
To assess for perturbations in the expression of selected candidate genes in APS-1 patients at 
the protein level, a flow cytometry panel was developed (table 3.1) and used for staining of 
PBMC samples from APS-1 patients and controls (figures 4.3-4.5, table 4.1). No large 
differences between the APS-1 patients and controls were found, although some interesting 
	 53	
trends are present. One interesting observation is a subtle decrease in the frequency of 
CD3+CD4+CD8-CD25+CD127- Tregs in the samples from the ASP-1 patients compared to the 
controls, which corresponds well with previous findings (Ryan et al., 2005; Wolff et al., 2010). 
Also, it is intriguing to observe a small decrease in the frequency of Helios+ and CD31+ cells 
within theCD3+CD4+CD8-CD25+FOXP3+ population. These findings could corroborate a 
previously suggested impairment of thymic generation of Tregs in APS-1 (Koivula et al., 2017).  
It could be that the AIRE-deficiency in APS-1 patients lead to impaired antigen presentation in 
the thymus, so that potential Tregs do not receive TCR signals within the appropriate affinity 
range for maturation. It is, however, worth noting the discrepancy observed between the result 
for HELIOS and Neuropilin-1. As both have been suggested to be markers of nTregs, it was 
surprising to observe that the frequency of Neuropilin-1 CD3+CD4+CD8-CD25+FOXP3+ cells 
was reduced for the patients compared to the controls. A potential explanation could lie with 
the low frequency of cells positive for Neuropilin-1, as this could negatively affect the 
reliability of the results. In addition, reliability of  HELIOS as a marker for nTregs is debated 
(Verhagen and Wraith, 2010; Himmel et al., 2013).  
 
A reduced frequency of naïve cells in APS-1 was indicated by a reduced frequency of naïve 
CD45RA+ cells among the CD3+CD4+CD8-CD25+FOXP3+ population. By contrast, the 
frequency of cells positive for as Ki67, CTLA-4 and CD39 was reduced, markers indicating 
cellular proliferation and an active Treg state (Ring et al., 2009).  For CTLA-4, intracellular 
expression has been indicated to be constitutive, while recycling to the plasma membrane is 
dependent on activation (Mead et al., 2005). It could be envisioned that, in the APS-1 patients, 
an increased presence of reactive T cells  (Liston et al., 2003) causes an increased likelihood of 
Treg activation, and that this is the explanation for these observations. Based on the results, it is 
tempting to speculate that Tregs in APS-1 maintains the ability to react to encounters with self-
reactive T cells by inducing increased proliferation and an active phenotype. The activation 
status of Tregs in APS-1 patients has been discussed by two previous publications, with opposing 
conclusions (Kekäläinen et al., 2007; Laakso et al., 2010).  
 
It should be clearly stated that great caution is required in the interpretation of the flow 
cytometry findings. One issue is the low abundancy of the Treg population in PBMC samples. 
This would be of especial concern with regard to the rarer markers, as exemplified by 
Neuropilin-1. To alleviate this issue, the ideal solution would be to increase the number of 
PBMC used. Unfortunately, this was not achievable due to the need to avoid excessive blood 
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sampling of the patients. Another issue is the large inter-individual variation observed. Such 
variations could be due to factors such as age or sex, for instance, the frequency of CD45RA+ 
Tregs has been reported to be decreased with increasing age (Booth et al., 2010). This trend was 
observed within the control group (figure 4.7). Other factors, such as recent infections, would 
also be a cause of confounding variation. To reduce such factors a larger data set encompassing 
a higher number of individuals should ideally be in place, in addition to age- and sex- matching 
between the patient and control group. Unfortunately, such measures were not feasible within 
the frame of the current project. As it is, none of the observed trends were found to be significant 
at the 5% level by application of a two-tailed Mann-Whitney test (table 4.1). 
 
To determine whether any changes in expression levels of selected candidate genes between 
APS-1 patients and controls could be observed at the RNA level, qPCR was used for assessment 
of both PBMC and Treg samples. By this approach, we have shown a substantial increase in 
expression of FOXP3, and lower increases in the expression of other Treg-associated genes, in 
Tregs relative to PBMC from the same individual (figure 4.8). We have also shown that no large 
differences were observed in the expression of any of the assessed genes when comparing APS-
1 patients and healthy controls, although a minor decrease in ENTPD-1 expression in the PBMC 
from the APS-1 patients compared to control PBMC was observed (figure 4.9). This finding is 
in disagreement with the findings for the corresponding protein product, CD39, in the flow 
cytometry experiment. The cause could potentially lie in regulatory mechanism at the level of 
translation, although a likely explanation would be that the experimental set-up yielded an 
insufficient sensitivity for reliable detection of subtle changes. 
 
The upregulation of a number of Treg-associated genes in Tregs compared to PBMC from the 
same individuals was an expected result, and increased the confidence in the cell sorting 
approach and the qPCR protocol. A puzzling observation, however, was that of a slight increase 
in AIRE expression in Tregs relative to PBMC (figure 4.8). A low level of AIRE expression in 
peripheral cells has been reported by previous studies (Gardner et al., 2008; Suzuki et al., 2008). 
However, it was surprising to also find AIRE expressed the Treg samples, as this has never been 
shown. A factor reducing the fidelity of this result is the low expression levels of AIRE, an issue 
could have been alleviated by the use of higher input concentrations. On the other hand, this 
would have reduced the number of genes that could be assessed with the available sample 
material, and the selected standard input was hence considered a reasonable compromise.  
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Another confounding factor could be the choice of reference gene, as the expression of the 
selected gene potentially could vary between PBMC and Treg samples. Reports are in 
disagreement regarding the fidelity of commonly used reference genes (Thellin et al., 1999; 
Livak and Schmittgen, 2001; Radonić et al., 2004), and the decision to use B2M was based on 
previous experience within the research group. Limited assessment of S18 as reference was 
performed (data not shown), and the result was found to be slightly deviating from those 
obtained with B2M. The use of a mean value based on assessment of several reference genes 
would have been the method of choice, had sufficient sample material been available.  
 
To enable assessment of gene expression at the RNA level by limited amounts of sample input, 
a RNA-seq protocol for samples of 5000 cells was developed. This protocol was subsequently 
employed for Tregs from APS-1 patients and controls. Based on the obtained data for a number 
of pre-selected candidate genes, most did not exhibit significant changes in expression levels 
in the patients compared to controls. The exception was mTOR, which exhibited a significant 
increase in expression in the APS-patients versus controls. It could be hypothesized that an 
increased mTOR level would negatively affect the ability of Tregs to maintain lineage identity 
and mediate suppressive function, as down-modulation of mTOR activity has been linked to 
the integration of IL-2 signaling and FOXP3 expression (Delgoffe et al., 2009). In support of 
this view, transient inhibition of mTOR by rapamycin has been indicated to increase Treg cell 
proliferation (Procaccini et al., 2010). A rapamycin-induced expansion of Tregs has been 
suggested as a contributing cause in the beneficial effects of this compound in treatment of 
systemic lupus erythematosus (Fernandez et al., 2006; Kato and Perl, 2014). 
 
The candidate genes were selected based on previous knowledge of their roles in Tregs and their 
previously reported utility in describing relevant features of the cells, such as origin and 
activation status. The decision to use an approach based on candidate genes was based on its 
potential for yielding a detailed understanding of specific mechanisms hypothesized to be 
relevant. However, this only gives a limited picture and prevents considerations of the overall 
situation.  If such an overview is the goal, a wider search is necessary. 
 
5.3 The expression levels of a number of genes are perturbed in Tregs from APS-1 patients  
A global search for gene expression level perturbations was performed based on the RNA-seq 
data. By this approach, we have shown that a number of genes exhibit significant differences 
in expression levels between APS-1 patients and controls (figure 4.13).  
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Among the genes exhibiting the largest decrease in expression levels in APS-1 patients 
compared to controls (figure 4.14) were TRBV7-9, encoding the 7-9 variable domains of the 
TCR receptor b chain (Hedlund et al., 2013), CAMLG, which blocks a calcium-dependent 
signals from the T-cell receptor that normally leads to T cell activation (Bram and Crabtreet, 
1994), GPR15, a chemoattractant receptor involved in the homing of T cells to the colon (Kim 
et al., 2013), and TRDC, encoding the bchain of the T cell receptor constant domain (Biondi et 
al., 1989). Other interesting genes among this group is CDK7 and BORA, involved in cell cycle 
progression (Rochette-Egly et al., 1997; Seki et al., 2008). If the cell cycle progression of Tregs 
in APS-1 patients is reduced, this could be envisioned to reduce their ability for clonal 
expansion upon encounter with autoreactive T cells.  
 
Among the group of genes exhibiting the largest increase in expression levels in APS-1 patients 
compared to controls (figure 4.15) include SKI and NOTCH1, which both may affect TGF-b 
signaling (Sun et al., 1999; Blokzijl et al., 2003). As TGF-b has been linked to Treg suppressive 
function and to the induction of Treg lineage identity in the periphery (Nakamura, Kitani and 
Strober, 2001; Fantini et al., 2004), this is an intriguing finding. Equally intriguing is the 
increased expression of INPPL1, encoding the SHIP2 protein involved in negative regulation 
of the PI3K pathway (Clément et al., 2001), especially considering the reported link between 
PI3K signaling and mTOR (Delgoffe et al., 2009). As an interaction between the CREB-
binding protein and AIRE has been reported  (Pitkänen et al., 2000), it is also interesting to see 
an increase in the expression of SCRAP, an activator of the CREB-binding protein (Johnston et 
al., 1999). Finally, it is worth mention that an increase was also observed in the expression of 
FBOXO41, which encodes a member of the F box protein family. F box proteins constitute a 
part of the SCF (Skp, Cullin, F-box containing) complex, which has E3 ubiquitin ligase activity 
(Zheng et al., 2002). Downstream of this complex are signaling pathways involved in regulation 
of the cell cycle and in regulation of signaling though MCH class II (Chang et al., 1996; Matsuki 
et al., 2007) . 
 
It is worth noting that the number of transcripts in the input samples would affect the result. For 
genes with a low number of transcripts, the reliability of the assessment would be reduced, as 
failure to detect any one transcript would cause large effects. It could also be envisioned that 
the pre-amplification step has the potential to cause undesired biases on the obtained results. 
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Ideally, the number of biological replicates should be increased in order to increase fidelity un 
in the results.  
 
Finally, it should be pointed out that medications frequently prescribed to APS-1 patients, such 
as cortisol replacement therapy in the case of adrenal insufficiency, may have impacts on the 
immune system. This could affect the results of all the applied techniques.  
 
5.4 Conclusions 
In summary, some subtle trends could be observed when comparing the expression of selected 
candidate genes in APS-1 patients and controls at the protein level. The trends would 
corroborate a view where the thymic development of Tregs could be affected, but the Tregs that 
manage to complete maturation and emigrate to the periphery retain their capability for 
activation upon encounters with self-reactive lymphocytes. However, these observations failed 
to reach statistical significance, and are not supported by assessment at the RNA level. Hence, 
if such differences are present, they appear to be subtle and more sensitive approaches would 
be needed for reliable detection.  
 
An exception to the lack of statistical significance is a detected perturbation of mTOR 
expression by the RNA-seq experiment. As mTOR already is being scrutinized as a potential 
target for therapy in other autoimmune diseases, this was a highly interesting finding. The 
RNA-seq experiment also enabled a global search for expression level perturbations, not limited 
to pre-selected candidate genes. By this approach, significant differences in expression levels 
of a substantial number of genes was found when comparing APS-1 patients and controls. It 
thus appears that, even though the candidate gene-based approach yielded few clear 
perturbations in APS-1, such perturbations do exist. To validate these findings and to explore 
their functional relevance, further experiments would be required.  
 
5.5 Future perspectives 
Current knowledge of Treg biology is rapidly expanding, and substantial efforts are being 
undertaken in order to implement clinical uses of this cell population. For instance, significant 
perturbations has been discovered in the Treg gene expression profile in pediatric patients with 
type 1 diabetes, yielding potential biomarkers for diagnostic use (Pesenacker et al., 2016). 
Encouragement of  the Treg-mediated tolerance mechanism in patients with immune-mediated 
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diseases, for instance by IL-2 treatment or adoptive Treg transfer, has been studied with 
promising results (Koreth et al., 2011; Lutterotti et al., 2013; Noyan et al., 2017). However, 
many questions still remain regarding Tregs and their role in autoimmunity. Continued work on 
human samples would be necessary in order to confirm whether current knowledge from murine 
models is consistent with the situation in humans, as it has been indicated that inter-species 
differences in thymic development may exist (Kekäläinen et al., 2007). Expanding the search 
for perturbations in APS-1 in particular could lead to the discovery of biomarkers with clinical 
value for patients with this condition. As APS-1 constitute an interesting model disease for 
autoimmunity, knowledge of basic immunology mechanism can be elucidated by work on this 
condition, and considerations regarding potential transfer value to other autoimmune diseases 
would be highly relevant. Finally, expanded knowledge regarding communication across 
immune cell populations would be a requirement for the safe and successful adoption of Treg-
based therapies in clinical practice. 
 
To answer these questions, continued effort into improving methodologies would be necessary. 
Single-cell based approaches especially could prove highly useful. Tregs represent a small cell 
population, so techniques requiring low input would enable studies into these cells without the 
need for drawing excessive volumes of peripheral blood. Also, single-cell analysis would 
facilitate the assessment of subpopulations within the Treg populations, for instance, it would be 
possible to say that a particular cell appears to be an nTreg or an iTreg, and see whether cells 
falling into either of these two categories showed any significant differences. Previous reports 
have indicated qPCR to be achievable, although a pre-amplification step, potentially causing 
undesired effects,  would likely be required (Pop et al., 2005; Flatz et al., 2011; Shalek et al., 
2013). A low-input RNA-seq protocol was successfully implemented in this project, and this 
protocol could likely be optimized for use on single-cell samples. As this experiment identified 
a number of genes with significant perturbations in the expression levels in APS-1, such as 
mTOR, SKI and NOTCH1, further assessment of these genes and the molecular pathways they 
are involved in would be highly relevant. To assess the capabilities of the Tregs to respond to 
extracellular signals, flow cytometry of cells after stimulation would be interesting. The flow 
cytometry studies could be complemented by additional protein-level techniques, for instance 
fluorescence microscopy or CyTOF. Another exciting prospect would be the use of the novel 
10X Chromium technology for single-cell analysis both at the protein and the RNA level 
(Zemmour et al., 2018). With continued methodological advancement, it would seem 
reasonable to expect highly interesting discoveries regarding Treg biology in the future.
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Abbreviations 
APC: Antigen-presenting cell 
AIRE: Autoimmmune regulator 
APECED: Autoimmune polyendocrinopathy-candidasis-ectodermal dystrophy 
APS-1: Autoimmune polyendocrine syndrome 1  
BSA: Bovine serum albumin 
CBP : CREB-binding protein 
CCR: Chemokine receptor 
CD: Cluster of differentiation 
CNS2: Conserved non-coding sequence 2 
CREB protein: cAMP response element binding protein 
CTL: Cytotoxkic T cell 
CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4 
CXCR: C-X-C motif chemokine receptor 3 
CXL1: C-X-C motif ligand 1 
DC: Dendritic cell 
DMSO: Dimethyl sulfoxide 
DN: Double-negative  
DP: Double-positive  
EDTA : Ethylenediaminetetraacetic acid 
ENTPD-1: Ectonucleosidase triphosphate diphosphohydrolase 1 
FACS : Fluorescence-activated cell sorting 
FEZF2 : Fez family zinc finger protein 2 
FoxO: Forkhead box O 
FOXP3: Forkhead box P3 
GITR: Glucocorticoid-induced TNFR family related gene 
IDO: Indoleamine 2,3-dioxygenase 
IKZ: Ikaros family zinc finger proteins 
IL: Interleukin 
IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome                      
 iTreg: Induced regulatory T cell 
LFA-1: leukocyte function-associated antigen-1 
MHC: Major histocompability complex 
mTEC: Medullary thymic epithelial cell 
mTOR: Mammalian target of rapamycin 
Nrp-1: Neuropilin-1 
nTreg: Natural regulatory T cell 
NT5E: 5’ nucleotidase ecto 
PAMP: Pathogen-associated molecular pattern 
PBS: Phosphate-buffered saline 
PBMC: Peripheral blood mononuclear cell  
PECAM: Platelet endothelial cell adhesion molecule 
PI3K: Phosphoinositide 3-Kinase 
PKB: Protein Kinase B
PTEN: Phosphatase and tensin homolog 
SCID mice: Severe combined immunodefiency mice 
SP: Single-positive
STAT: signal transducer and activator of transcription 
TCR: T cell receptor 
TH cell: Helper T cell 
TGF-b: Transforming growth factor b 
TMP:  Transcript per million
TNFR: Tumor necrosis factor receptor 
TOLLIP: Toll-interacting protein 
TRA: Tissue-restricted antigen 
Treg: Regulatory T cell
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No. Sex Age Age of 
debut 
Manifestations AIRE mutation Auto-antibodies 












Side chain cleavage enzyme 
Tryptophan hydroxylase 
NOD-liker receptor phyrin 










NOD-liker receptor phyrin 
domain containing 5 
17-hydroprogesterone 
Interferon-w 
3 Male 55 43 Hypoparathyroidism 







Aromatic I-amino acid 
decarboxylase 
Glutamic acid decarboxylase 
Tryptophan hydroxylase 
NOD-liker receptor phyrin 










Side chain cleavage enzyme 
Glutamic acid decarboxylase 
Interleukin-22 
Interferon-w 
5 Female 42 Un-
known 
Hypoparathyroidism 
Primary ovarian failure 
Enamel dysplasia  
Autoimmune thyroiditis  
Vit B12 deficiency 
c.934G>A NOD-liker receptor phyrin 
domain containing 5 
Interferon-w 
 




NOD-liker receptor phyrin 
domain containing 5 
Interferon-w 
Table S.1: List of the included patients with information about sex, age, AIRE-mutation, auto-antibodies, 
diagnosis and age of disease debut. Among the recruited patients, two different AIRE mutations were 


























No. Sex Age Included in 
1  Male 35 Protein profiling and RNA study (qPCR, PCR and RNA-seq) 
2 Male 53 Protein profiling and RNA study (qPCR) 
3 Male 43 Protein profiling study  
4 Male 48 Protein profiling study 
5 Male 52 Protein profiling study 
6 Male 66 Protein profiling study and RNA study (qPCR and RNA-seq) 
7 Female 25 Protein profiling study and RNA study (qPCR and RNA-seq) 
8 Male 33 RNA study (RNA-seq) 
9 Male 60 RNA study (qPCR) 
10 Male 30 RNA study (qCR) 
11 Male 43 RNA study (qPCR) 
12 Male 27 RNA study (qPCR) 
Gene Forward primer  Reverse primer 
B2M ATGTCTCGCTCCGTGGCCT TCCACTTTTTCAATTCTC 
IKZF4 CAGCGTGATTGTGGAAGA GACTCTGTAGGTAGTTAT 
PECAM-1 ACCAGGTGTTGGTGGAAGGAGTG AACTTGGGTGTAGAGAAG 
CXCR3 CTACACCGAGGAAATGGG TGCAACTGCCCAGAAGGGA 
CD3d ATGGAACATAGCACGTTT AAAGCAAGGAGCAGAGTGGC 
mTOR TGGAACTCCGAGAGATGAGTCA AGGCTTCTGCATCTCCTT 
TOLLIP ATGGCGACCACCGTCAGCA TCGTACACCGCGTAGCCCAG 
FOXO1 TCAACATCAGGCACTTCTCAGAGTA  TACTTGGAAAGTTCTGCTTTGACA 
CCR5 AGTGTGATCACTTGGGTGGTG TGGTGAAGATAAGCCTCACAGC 
Neuropilin-1 CTTGGATTTCGCTCAGTTTCCAAA TCGTGCTGTACTGTGCCTGTTG 
CCR4 CTGTATTCCTTGGTTTTTGT AGGTCCTTGCCCTCAAGGA 
 Flow cyt. qPCR RNA-seq Function 
FOXP3 X X X Trancription factor for genes involved in Treg 
function and lineage stability 
AIRE  X  Transcription factor, TRA expression  
CD152/CTLA-4 X X X Mediates suppressive function of Tegs 
HELIOS/IKZF2 X  X Trancripton factor 
Neuropilin-1 X X X Co-receptor for semaphorin and vascular 
endothelial grown factor 
CD39/ENTPD-1 X  X Hydrolysis of ATP and ADP 
CD31/PECAM-1 X X X Cellular migration 
GITR/TNFRSF18  X X Cell surface receptor on T lymphocytes 
Ki-67/MKI67 X  X Involved in cell cycle progression 
CD45RA/PTPRC X  X Protein tyrosine kinase 
Eos/IKZF4   X Transcription factor 
CXCR3   X Chemokine receptor 
CD3d   X Part of the TCR constant domain 
mTOR   X Cell signalling 
TOLLIP   X Adaptor protein of the toll-like receptor 
FOXO1   X Transcription factor, induces expression of FOXP3 
CCR5   X Chemokine receptor 
CCR4   X Chemokine receptor 
CD73/NT5E   X Hydrolysis of AMP 
Table S.3: List of the genes assessed in the conventional PCR protocol, with the sequences of forward and reverse 
primers for each gene.  
Table S.2: List of the controls included in the specific studies with information about sex and age 
Table S.4: List of the selected candiate genes 
